Prevalence estimation of essential tremor in Hungary between 2010 and 2020 based on the National Health Insurance Fund database

Prevalence estimation of essential tremor in Hungary between 2010 and 2020 based on the National Health Insurance Fund database | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Prevalence estimation of essential tremor in Hungary between 2010 and 2020 based on the National Health Insurance Fund database Andrea Kinga Papp, Ádám József Berki, Péter Vinnai, András Ajtay, and 3 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-6140908/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 05 Aug, 2025 Read the published version in Scientific Reports → Version 1 posted 8 You are reading this latest preprint version Abstract The published prevalence of essential tremor is variable worldwide and lacking in Central Europe. We aimed to estimate its prevalence in Hungary and to explore the locally applied therapeutic approaches. We collected data from the National Health Insurance Fund database and pharmacy database registered between 2010 and 2020. Matching the specified codes of the International Classification of Diseases and the individually tailored combination of interventions, we attempted to exclude Parkinson’s disease and other tremor evoking conditions. We estimated the period prevalence of essential tremor age standardized to the European Standard Population at 378–388/100,000. After excluding patients with possible Parkinsonian syndromes, we found that 36.4% of patients with tremor did not take any medication during the study period. Most of the rest used alprazolam followed by propranolol for the longest period of time; the alprazolam and propranolol combination was the most preferred. Deep brain stimulation and ablative surgery were chosen for less than 0.5% of the patients. Our strict methods probably underestimate the essential tremor prevalence in Hungary, which, however, does not differ considerably from international results. Given the limitations of medication therapy, expanding and improving neurosurgical interventions may help improve the quality of life of patients with essential tremor. Health sciences/Diseases Health sciences/Health care Health sciences/Neurology epidemiology essential tremor Hungary prevalence therapy tremor Figures Figure 1 Figure 2 Figure 3 Figure 4 Introduction Essential tremor (ET) is an isolated tremor syndrome of bilateral upper limb postural or kinetic tremor, sometimes accompanied by head tremor or tremor in other body parts 1 . Its differential diagnosis is often a challenge. Essential tremor associated with soft neurological signs, such as impaired tandem gait, mild memory impairment, or subtle dystonic posturing, is labeled essential tremor plus (ET plus) syndrome. Tremor appears in several neurodegenerative, mitochondrial, infectious, endocrine, or metabolic disorders, or it is evoked by some frequently administered drugs or toxins 1 . In the early stages of Parkinson’s disease, essential tremor is the most common misdiagnosis 2 . Although essential tremor is a benign disorder, it can substantially decrease the quality of life 3 , as many patients experience a regular and consistent worsening in their condition 4 . Furthermore, many patients feel hopeless in coping with their illness; demoralization was found to be nearly as frequent in essential tremor as in chronic or terminal diseases, such as in cancer, coronary heart disease, or Parkinson’s disease 5 , highlighting the need to discover local therapeutic habits in this patient population. In evidence-based recommendations, propranolol, primidone, and topiramate (in a daily dose higher than 200 mg) were categorized as clinically useful, while alprazolam as possibly useful in ET 6 , 7 . Propranolol and primidone are frequently administered in combination because they synergize 8 . Botulinum toxin A may have a beneficial effect in selected cases 9 . Unilateral stimulation of the ventral intermedial nucleus of the thalamus, unilateral focused ultrasound thalamotomy, as well as radiofrequency thalamotomy, are possibly effective in essential tremor with acceptable risks, according to the latest guideline 6 . Bilateral neurosurgical procedures are still under investigation for creating evidence-based recommendations on their use; however, according to expert opinion, similarly to unilateral surgery, they offer better outcomes (with an estimated improvement of around 80%) than medication therapies 7 . Essential tremor is considered to be one of the most common movement disorders in adults; it is up to 4–5 times more common than Parkinson’s disease in previously published studies 10 – 12 . Its prevalence after the age of 65 years is close to that of Alzheimer’s disease 13 . There is remarkably less epidemiological data from Europe than from the Asian continent 14 . The prevalence of essential tremor has been studied in only a few European countries (Finland 15 , Italy 16 , 17 , Spain 18 , Faroe Islands 19 ) and not in the Central European regions; the prevalence of ET in these countries ranges from 0.4% 16 to 1.4% in the general population 20 and up to 8.6% in people over 65 years 18 . Some population-based studies investigate only small geographical territories 19 , 21 . In this study, we aimed to calculate the ET prevalence in Hungary, despite the difficulties of its differential diagnosis; and to analyze the use of available therapeutic approaches recommended by international guidelines. We wanted to explore the necessary public health resources and the nationally unmet challenges for preparing public health actions 14 to optimize the care of ET. Results Grouping the multiple causes of tremor Figure 1 depicts the flowchart of the patient selection. We found 76,631 patients (Group 1) who received any of the four specified tremor ICD-codes between 2004 and 2020 (the mean age at the first tremor diagnosis was 57.45±23.14 years, 45.51% male). Due to the limited access to the pharmacy database of medication refills (2010-2020), we excluded 16,955 patients (Group 3) who only received tremor codes between 2004 and 2009. There were 7,317 patients included in the study who not only had their first tremor diagnosis between 2004 and 2009, but also had tremor ICD-codes between 2010 and 2020. Finally, we analyzed 59,676 patients (Group 2) who received tremor codes during our actual study period between 2010 and 2020. We excluded 13,758 patients (Group 5) from the analysis for lack of a sufficient two years’ follow-up period. There were 45,918 patients (Group 4) with a minimum of two years of observation time; they were further investigated regarding medication use and differential diagnosis. A group of 5,206 patients (Group 7) used antiparkinsonian medications in at least 80% of the study period, starting after the initial 2 years following their first tremor diagnosis; this group of patients was considered to have Parkinson’s disease/syndrome and thus were separated from the Not Parkinsonian Tremor Group (Group 6). In the Not Parkinsonian Tremor Group, we explored the likelihood of each alternative diagnosis outside Parkinsonian syndromes and additional signs associated with tremor, which was less than 1% (Table 1). In the Not Parkinsonian Tremor Group, the ratio of patients taking amiodarone, valproate, and l-thyroxin varied between 1-3%; the ratio was lower for lithium (Table 1). Overall, 3,463 patients (Group 9) had at least one alternative or additional diagnosis/sign and/or had consumed at least one of the potentially tremor-inducing medications. In the case of 37,249 patients (Group 8), these methods excluded alternative causes of tremor, so they were considered to have most probably essential tremor. Therapeutic approaches Regarding pharmacological approaches, we found that in the Not Parkinsonian Tremor Group (Group 6), 14,825 patients (36.41%) never tried any of the five studied medications (propranolol, primidone, topiramate, alprazolam, and clonazepam). A group of 7,459 patients (18.32%) consumed any of these medicines in less than 20% of the follow-up period. Based on this data, 22,284 patients (54.73%) did not consume any specific medication in at least 80% of the investigated time interval. Alprazolam was dispensed to 44% of those patients who were taking any of the studied medications. (Figure 2). Furthermore, Table 2 shows that among medications taken at least once during the study period, the highest percentage of patients preferred benzodiazepines. Among the five studied antitremor medications, 11,943 patients utilized alprazolam for the longest period of time (Figure 3). The duration of medication use, when the patients refilled the listed drugs from the pharmacy, differed significantly (p < 0.0001), the longest being for alprazolam and the shortest for topiramate. Post hoc tests showed that the difference was significant between each medication (p 0.05) (Figure 4). When the pharmaceutical options were combined, the alprazolam - propranolol therapy was the most common (Table 3). Less than 0.5% of the patients underwent neurosurgical procedures such as deep brain stimulation or ablative surgery (Table 2). In relation to the total number of patients in the Parkinson's tremor and Not Parkinsonian Tremor Group, less than 4% of patients were later switched from antiparkinsonian therapy to other antitremor therapy, while less than 3% were initially on other anti-tremor drugs that were later changed to antiparkinsonian drugs (Table 4). Prevalence of essential tremor Our methods identified 37,429 patients with essential tremor (mean age at first tremor diagnosis: 54.93 ± 23.4 years, 44.73% male). Using the population data from the 2011 Census in Hungary 22 , the estimated period prevalence of the disease was 374/100,000. The age-standardized period prevalence of essential tremor for the European Standard Population of 2013 23 was 388/100,000. If we utilize the results from the Hungarian Census in 2022 24 , the period prevalence of essential tremor was 387/100,000 in Hungary; when standardizing it to the European Standard Population of 2013, it was 378/100,000. The stratified age and gender analysis in the Probably Essential Tremor Group (Group 8) showed the highest prevalence in the elderly population (1.29 % among men and 1.25% among women aged 70-79), the prevalence was similarly high in people over 80 years (0.82% in men and 0.79% among women) and those between 60 and 69 years of age (0.74% for both gender groups). When evaluating by gender, the overall prevalence was 0.35% among men (0.39%) and women (Table 5). When compared to data from other European countries, the estimated prevalence of essential tremor in Hungary is similar to the one assessed in Italy (405/100,000) 16 but lower than in the Faroe Island 19 , Finland 15 , and Spain 18,25,26 (Table 6). Discussion In this study, we found that the period prevalence of essential tremor standardized to the European Standard Population was approximately 0.378–0.388% between 2010 and 2020 in Hungary. Alprazolam followed by propranolol were chosen for the longest time period by most of the patients. The propranolol-alprazolam combination was taken in the highest percentage of the medication period by most of the patients. Among neurosurgical procedures deep brain stimulation and ablative surgery were applied in less than 0.5% of the patients, with a possible diagnosis of essential tremor. Recognition of essential tremor in a broad national health insurance fund database is challenging as standard tests do not support the differential diagnosis processes, which rely on clinical observation 27 . Misdiagnosis is more likely to occur when its severity is subtle 28 . Some studies indicate that the diagnosis of essential tremor is over-applied, with many of the patients having other movement disorders, most commonly Parkinson’s disease or dystonia 28 , 29 . Tremor is indeed described as a common prodromal presentation of Parkinson’s disease 30 . Physiological tremor is also among the most common alternative diagnoses 31 . Thus, we have attempted to narrow down the population of patients with tremor to essential tremor, based on co-diagnoses and medication use data. The Hungarian healthcare system has a single health insurance fund managed by the Health Insurance Fund Management Agency (NHIF) 32 . Every Hungarian citizen has a personal identifier 33 , and all their medical records from hospitals and outpatient services are linked to this identifier and recorded in the database we used. State health expenditure in relation to GDP in 2021 was 7.4% in Hungary compared to 11% of the EU average 34 . Between 2000 and 2018, 25–30% of the healthcare expenditure was financed by individuals and private companies 35 , but detailed data on each field of the private medical system is scarce. An available survey from Hungary, in which 1100 people were asked, found that among those who sought private medical help, 3% chose neurology 36 . If we extrapolate this finding, excluding private healthcare would introduce only an approximately 1% (30% x 3%) bias in our findings. In the study period, we initially had 59,676 patients with tremor ICD-10 (International Classification of Diseases-10) codes. Since a short observation time increases the likelihood of misdiagnosis 28 , we excluded patients with less than two years follow-up period from further analysis. As the next step, we endeavored to screen out patients with Parkinson’s disease, trusting in their need for continuous medication use, which may be initiated after the first years from symptom onset in agreement with the patient 37 . When the patient took antiparkinsonian medication in at least 80% of the total follow-up time, excluding the initial two years, the patient was considered to have Parkinson’s disease/syndrome. In the remaining Not Parkinsonian Tremor Group, we sorted out patients with alternative causes and co-existing symptoms and tremor-inducing/intensifying medication therapy. Among the conditions, alcohol abuse and hyperthyroidism, among the medications, amiodarone was the most commonly found factor. We saw at least one provoking condition or medication in approximately 9% of the cases. Even though the use of tremor-evoking/enhancing medications does not preclude an underlying essential tremor, we separated this small group of patients to get an estimate that was as accurate as we could ascertain. Finally, we were left with 37,249 people with most probably essential tremor. There is a marked heterogeneity in prevalence estimates in essential tremor, ranging from 0.01–20%, greater than that reported for many other neurological diseases 14 . A systematic review published in 1998 concluded that the prevalence of essential tremor might range from 0.4 to 3.92% across different populations. However, no meta-analysis could be performed on this data because of the disparate methodologies 38 . There are three published meta-analyses on essential tremor prevalence 14 , 39 , 40 . In the first one from 2010 39 , the overall prevalence of 28 population-based studies was 0.9% (all ages, limited external validity); in an additional descriptive review of two studies (reported about the patient examination and sensitivity of the methods), the prevalence was 0.4% (all ages). Since more population-based prevalence data became available, the same group conducted another meta-analysis in 2021 14 . Based on 42 studies, they reported a pooled prevalence of 1.33% of the disease (all ages) 14 . A descriptive analytical approach of three studies (reported about the patient examination and sensitivity of the methods) revealed that the median prevalence of essential tremor was 0.4%, and the mean was 0.67% (all ages) 14 . Another meta-analysis from 2021 based on 29 population-based studies reported a prevalence of 0.32% (all ages) 40 , which is comparable to our findings. Direct comparison of prevalence data in the different meta-analyses is not possible because the proportion of studies conducted in middle-aged (≥ 40 years) or elderly (≥ 60 or ≥ 65 years) populations vary, influencing the results as the prevalence is known to increase with age 40 . However, the estimated prevalence of essential tremor is highly heterogeneous 14 ; it ranges from 0.01% 41 to 20% 11 , behind which there may be several factors. Even though essential tremor can also be present in the pediatric population 42 , many of the population-based prevalence studies only investigate older people 11 , 18 , 21 . However, the age of onset has two peaks: the smaller proportion of young onset cases culminated in their twenties and a more prominent peak given by the sporadic cases starting above 60 years of age 43 . Essential tremor becomes more common with advanced age: the prevalence was indeed shown to increase by 74% for every decade increase in age 14 . The estimated prevalence of essential tremor among the elderly, aged 60 or older, ranges from 0.5% 44 to 26.1% 45 . A study analyzing a community in Nigeria found a 42.9% prevalence of ET in people aged 85 or older 45 . Males were more likely to be affected than females in many studies 15 , 17 , 46 , however the opposite tendency was also reported 47 , other studies found no gender differences in disease distribution 14 . However, the heterogeneity in prevalence data could not be explained by stratifying the data by age and gender 14 . When interpreting the results from other European countries, it is important to note that most of the data represent small geographical territories of each country 15 , 16 , 18 , 25 , 26 and investigate only older people population 18 , 25 , 26 , where the prevalence is known to be higher 40 . Only in Italy 16 was the study conducted on all age groups, and the results are similar to ours. None of the other studies analyzed therapeutic trends. Our results regarding the stratification analysis on age are congruent with the literature since the prevalence of essential tremor is higher in the elderly 40 . The prevalence of the disease is generally higher in males 40 , but other studies have also found a slight female predominance 47 , 48 . The mild symptoms of essential tremor may not require any treatment, and the pharmacological management of severe essential tremor is limited 8 . Our study found that over one-third of the patients never tried any of the five studied medications (i.e., propranolol, primidone, topiramate, alprazolam, and clonazepam). More than 50% of the patients did not consume these medications in 80% of the follow-up period. The most commonly used drug was alprazolam, followed by propranolol and clonazepam. Only a small proportion of patients consumed primidone, and less than 0.5% took topiramate. The effect of the therapies above (with an average improvement of 60%) is limited 7 , which, together with the side effects, the younger age of the patients, and more severe depression, may result in non-adherence 49 . Adherence to any medication is influenced by the effect of the drug on the symptom, its likely unpleasant side effects, and any possible comorbid effects 50 , 51 . We defined it with two measures in our study. First, with the number of patients to whom the given drug was dispensed at least once. Alprazolam was frequently refilled by the highest percentage of patients, which might be influenced by its anxiolytic effect 52 . A study conducted in the US found that 1–2% of the general population uses alprazolam 52 . This drug was taken by 44% of our Not Parkinsonian Tremor Group (Group 6) patient population, which, might not be attributed to its anti-anxiety effect alone. The second metric of medication adherence we investigated is how many patients refilled a particular drug for the most prolonged period of time. Alprazolam was taken for the longest time by the most patients, followed by propranolol, clonazepam, primidone, and topiramate. In our patient database, the combination of propranolol and alprazolam was the most preferred. The availability of medicines also influences medication habits. In Hungary, benzodiazepine preparations and propranolol can be prescribed by a general practitioner. In contrast, primidone can only be prescribed by a neurologist, and topiramate can be prescribed or authorized for up to one year by a neurologist. Botulinum toxin type A injection has an off-label indication in essential tremor 6 ; it is not covered by the national health insurance fund and hence was missing in the therapeutic approaches in our study. The widespread use of alprazolam might be associated with psychiatric comorbidities and the probably inappropriate prescription of the drug by physicians. A large retrospective study containing data from more than 120 thousand ET patients from the USA assessed the prevalence of comorbidities among the patients and found that 29% of them had an anxiety disorder, and depression was even more common (44%). They found that in 2019, benzodiazepines were only prescribed to 19% of the essential tremor patients 48 . Even if we extrapolate this finding, the proportion of patients with anxiety would still not fully explain the much higher percentage (44%) of our patients taking alprazolam. Therefore, other factors contribute to it as well. Studies on the rate of the population using benzodiazepines in Hungary have not been conducted yet. A cross-sectional study from the US analyzing drug utilization among more than 36,000 ET patients found that 17% had at least one prescription for a benzodiazepine 53 . A smaller study of 1,074 ET patients in the US reported that only 2% of the drug prescriptions were for benzodiazepines, specifically clonazepam and diazepam; alprazolam was not studied 54 . A study investigating the global use of benzodiazepines (namely the defined daily dose (DDD) per 1000 inhabitants per day) found that this metric is more than twice as high in Hungary compared to the average worldwide consumption; however, the study does not contain data on the percentage of the population or the exact number of people taking these drugs 55 . Regarding the European population, a cross-sectional study conducted in 2019–2020 in seven European countries (Czech Republic, Serbia, Estonia, Bulgaria, Croatia, Turkey, and Spain) found that 14.9% of the investigated older adults (aged 65 or older) were benzodiazepine users, in Croatia, Spain, and Serbia the proportion was more than 30% 56 . In France, benzodiazepines were prescribed to 12.5% of the adult population 57 . It was revealed in Brazil that primary health care is the most significant source of benzodiazepine prescription, which is frequently inappropriate 58 . Future research focusing on psychiatric comorbidities among the essential tremor patients in Hungary could explore the cause of high alprazolam consumption in this patient population. At the time of the study, a small number of patients had switched from antiparkinsonian therapy to other tremor therapy and vice versa. These results also corroborate the diagnostic difficulties in the first period of the disease 28 , 29 ; however, they were rare in our study. Our data indicated that during this 11-year long time interval, only a small proportion of the essential tremor patients were operated on: 0.39% of the patients received deep brain stimulation, and the number of those who underwent lesioning/ablative surgery was remarkably lower than that. MRI-guided ultrasound thalamotomy was unavailable in the study period and is still unavailable in Hungary. After its introduction in 2016, there have been an increasing number of MRI-guided ultrasound thalamotomies each year, with almost 2000 procedures in 2022 in the United States 59 . ET represented 24% of all DBS indications in the United States between 1993 and 2017, with 1331 implantations per year 60 . According to this published data 60 , 2.7 times more DBS procedures were done for ET in the US than in Hungary per unit population in the time interval overlapping with the time of our study. Economic calculations show that the cost of deep brain stimulation is similar in studies performed in different countries from Europe, Asia and North America and between the distinct indications 61 . Magnetic resonance-guided focused ultrasound thalamotomy has a more favourable cost-effectiveness profile than deep brain stimulation in essential tremor 62 – 64 . When comparing focused ultrasound thalamotomy and no surgery in people ineligible for neurosurgical procedures with craniotomy, the former is cost-effective due to improved quality-adjusted life years 64 . In conclusion, Hungary's estimated prevalence of essential tremor is comparable to the global prevalence found in systematic reviews and meta-analyses. On the other hand, the high use of alprazolam and the small number of neurosurgical interventions require improvements in treatment planning at national level. Considering the global aging trend, an increase in essential tremor cases can be expected 40 . A broader use of neurosurgical interventions and the possible introduction of focused ultrasound therapy is proposed by conducting cost-effectiveness studies and, in parallel, by establishing national therapeutic guidelines and providing education to physicians. Limitations The prevalence of essential tremor may be underestimated as many patients do not consult a doctor with mild symptoms and do not take medication 14 . The prevalence determined was a rough estimate from the National Health Insurance Fund database based on physicians' coding of tremor diagnoses. Given the large number of patients, reviewing individual medical records was impossible. Nevertheless, we tried to refine it by a matched, parallel analysis of medication use data. We did not consider data from private care because they did not have mandatory reporting before June 01, 2020. Our database is anonymized, with no personal identifiers. Therefore, we were unable to validate a subset of cases from it. Consequently, we could not determine the exact values for the sensitivity and specificity of our methodology. A few factors could influence sensitivity and specificity, such as the reliance on ICD-codes and medication use and excluding private healthcare (approximately 1% bias). Analyzing regional or urban-rural differences in prevalence was impossible because the database does not contain information regarding patients' places of residence. Nevertheless, addressing this question in the future can further characterize the prevalence of essential tremor. Methods Description of databases and identification of tremor patients In order to estimate the prevalence of essential tremor in Hungary, we used two independent databases: the databases of the National Health Insurance Fund covering patient care from all hospitals and specialist outpatient services (between 2004 and 2020); and the pharmacy database of medication refills from all pharmacies throughout the country (between 2010 and 2020). The original patient identifier codes were anonymized and we used encrypted identifiers. The study was performed according to the Declaration of Helsinki. All personal data protection regulations were followed. The study was approved by the Medical Research Council of Hungary (ETT TUKEB IV/7136- 1 /2021/EKU). Due to the retrospective nature of the study, the Medical Research Council of Hungary waived the need of obtaining informed consent. Each patient had a constant encrypted identifier in the whole study period in the two distinct databases, allowing us to link the matching records. As pharmacy medication refills data were available only from 2010 on, we only analyzed the overlapping 11-year-interval between 2010 and 2020. In the first step we analyzed the inpatient and specialist outpatient databases and selected those who, during these years, received at least once a primary or secondary diagnosis of tremor (Group 2). We considered the reported tremor diagnoses if they were established by neurologists and other specialists. With this selection criterion, we included patients who might have only consulted with their general physician to reduce the possible underrepresentation of mild essential tremor cases. For the diagnosis codes we used the 10 th Edition of the International Classification of Diseases (ICD-10) and searched for the ICD-codes accordingly: G2500 (essential tremor), G2510 (drug-induced tremor), G2520 (other specified forms of tremor), R2510 (tremor, unspecified). As other symptoms of Parkinson's disease are likely to appear within two years of the onset of monosymptomatic tremor in Parkinson’s disease 65 , we restricted the study sample to patients with a documented follow-up period of at least 2 years during the study period (Group 4) to increase the robustness of the diagnosis. If patients died or our study period had come to an end within two years after receiving the first tremor diagnosis, we excluded that data from further analysis (Figure 1). Grouping the multiple causes of tremor As the next step, we sorted out patients with Parkinson’s disease (Group 7) using the following criteria: the pharmacy records had to indicate that the patient used antiparkinsonian medication in at least 80% of the follow-up time (Anatomical Therapeutic Chemical Classification System - ATC - code: N04). When calculating this ratio, we subtracted two years from the actual follow-up time of the patient because of the uncertainty of the diagnosis of Parkinson’s disease, which could lead to alternative treatment strategies. After removing the Parkinson's patients, the remaining group of patients (Not Parkinsonian Tremor Group: Group 6) was further investigated (Figure 1). In addition to Parkinson’s disease, other diseases or signs might also receive a tremor diagnosis code in the medical records. In Group 6, we searched for the following ICD-10 codes for alternative diagnoses in tremor syndromes: multiple sclerosis (G35H0, G3680, G3690, G3710, G3730, G3780, G3790), hyperthyroidism (E0510, E0530, E0600, E0610, E0620, E0640, E0650, E0690, E0780, E0790), alcohol abuse (F1010, F1020, F1030, F1040, R7800, T5180, T5190, Y9090, Y9100, Y9110, Y9120, Y9130, Y9190, Z7210) and Wilson’s disease (E8300) as well as for additional diagnosis or signs that could be associated with tremor: dystonia (G2400, G2410, G2420, G2440, G2480, G2490), torticollis (G2430) and blepharospasm (G2450). We also examined the refills of the following drugs, which may evoke enhanced physiological tremor: amiodarone, valproic acid, l-thyroxin and lithium. We have performed stratification analysis by gender and age in the Most probably Essential Tremor Group (Group 8, Table 5). Therapeutic approaches In the Not Parkinsonian Tremor Group (Group 6) we examined the pharmaceutical therapies from a number of different perspectives. Within the pharmacy database, we evaluated the use of the most frequently applied medications: propranolol, primidone, and topiramate for essential tremor, antiparkinsonian medications (ATC N04), and two benzodiazepines (alprazolam and clonazepam). For each drug, we collected the following information: the time of the first and last acquisition of medication during the study period, the interval between them, and the number of medication packages dispensed to the patient. We determined the number of patients to whom none of the selected medicines were dispensed for at least 20% of the study period. If the patients took medication, we observed which drug they preferred for the most prolonged time period. We then calculated the temporal ratio of each medication use individually, dividing the time interval of medication refills by the total follow-up time. We further investigated the drug combinations, the number of patients utilizing the combinations, the length of their utilization time period and the temporal ratio of their use were assessed. Furthermore, we looked into changes in therapy: we assessed the number of patients in Group 6 who first was on antiparkinsonian medications (ATC N04) and later switched to one of the antitremor drugs (propranolol, primidone, and topiramate, alprazolam and clonazepam). Among the patients who were finally considered to have Parkinson’s disease/syndrome (Group 7), we selected those who were first on an antitremor medication, and it was later changed to antiparkinsonian therapy. In addition to medications, we searched the database for surgical procedures, such as ablative surgery and deep brain stimulation. Statistical analysis The estimation of the prevalence of essential tremor in Hungary was based on the Hungarian population data. We calculated the crude period prevalence in Hungary using data from the Central Bureau for Statistics (Census 2011 22 and Census 2022 24 ). With the help of the direct standardization method, our results were age-adjusted to the European Standard Population of 2013. We also compared the results with existing prevalence data from other European countries. For data analysis, we used descriptive statistics. Normality was evaluated with Shapiro–Wilk test. We used OriginLab software (OriginLab Corporation, Northampton, MA, USA) for statistical analysis and data presentation. Krusall-Wallis test (one-way ANOVA on ranks) was used with the post-hoc Dunn's test to detect possible differences between the durations of medication use. Declarations Data availability statement The dataset for this study can be requested from the corresponding author by qualified researchers, in accordance with the limitations set by the ethical approval. Acknowledgements The work was partly supported by grant No.: TKP2021-EGA-25 of the National Research, Development and Innovation Office , Hungary Authors contributions A.K.P., A.J.B., P.V., A.A., D.B., L.E., G.T.: data collection, manuscript review, and critique. A.K.P., A.J.B., G.T.: data analysis. A.K.P., A.J.B., D.B., L.E., G.T.: experimental design. A.K.P., A.J.B., G.T.: manuscript writing. All authors have read and approved the final manuscript. Additional information Competing Interest Statement The authors have no competing financial and non-financial interest to declare. References Bhatia, K. P. et al. Consensus Statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society. Mov Disord 33 , 75-87, doi:10.1002/mds.27121 (2018). Tolosa, E., Wenning, G. & Poewe, W. The diagnosis of Parkinson's disease. Lancet Neurol 5 , 75-86, doi:10.1016/s1474-4422(05)70285-4 (2006). Lorenz, D., Schwieger, D., Moises, H. & Deuschl, G. Quality of life and personality in essential tremor patients. Mov Disord 21 , 1114-1118, doi:10.1002/mds.20884 (2006). Gutierrez, J., Park, J., Badejo, O. & Louis, E. D. Worse and Worse and Worse: Essential Tremor Patients' Longitudinal Perspectives on Their Condition. Front Neurol 7 , 175, doi:10.3389/fneur.2016.00175 (2016). Cersonsky, T. E. K. et al. Demoralization in essential tremor: prevalence, clinical correlates, and dissociation from tremor severity. CNS Spectr 25 , 16-23, doi:10.1017/s1092852918001633 (2020). Ferreira, J. J. et al. MDS evidence-based review of treatments for essential tremor. Mov Disord 34 , 950-958, doi:10.1002/mds.27700 (2019). Hopfner, F. & Deuschl, G. Managing Essential Tremor. Neurotherapeutics 17 , 1603-1621, doi:10.1007/s13311-020-00899-2 (2020). Sharma, S. & Pandey, S. Treatment of essential tremor: current status. Postgrad Med J 96 , 84-93, doi:10.1136/postgradmedj-2019-136647 (2020). Brin, M. F. et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology 56 , 1523-1528, doi:10.1212/wnl.56.11.1523 (2001). Attia Romdhane, N. et al. Prevalence study of neurologic disorders in Kelibia (Tunisia). Neuroepidemiology 12 , 285-299, doi:10.1159/000110330 (1993). Khatter, A. S. et al. Prevalence of tremor and Parkinson's disease. Parkinsonism Relat Disord 2 , 205-208, doi:10.1016/s1353-8020(96)00027-2 (1996). Moghal, S., Rajput, A. H., D'Arcy, C. & Rajput, R. Prevalence of movement disorders in elderly community residents. Neuroepidemiology 13 , 175-178, doi:10.1159/000110376 (1994). Hirtz, D. et al. How common are the "common" neurologic disorders? Neurology 68 , 326-337, doi:10.1212/01.wnl.0000252807.38124.a3 (2007). Louis, E. D. & McCreary, M. How Common is Essential Tremor? Update on the Worldwide Prevalence of Essential Tremor. Tremor Other Hyperkinet Mov (N Y) 11 , 28, doi:10.5334/tohm.632 (2021). Rautakorpi, I., Takala, J., Marttila, R. J., Sievers, K. & Rinne, U. K. Essential tremor in a Finnish population. Acta Neurol Scand 66 , 58-67, doi:10.1111/j.1600-0404.1982.tb03129.x (1982). Salemi, G. et al. Prevalence of essential tremor: a door-to-door survey in Terrasini, Sicily. Sicilian Neuro-Epidemiologic Study Group. Neurology 44 , 61-64, doi:10.1212/wnl.44.1.61 (1994). Mancini, M. L. et al. Prevalence of essential tremor in the territory of Lake Trasimeno, Italy: results of a population-based study. Mov Disord 22 , 540-545, doi:10.1002/mds.21349 (2007). Seijo-Martínez, M. et al. Prevalence of Essential Tremor on Arosa Island, Spain: a Community-based, Door-to-Door Survey. Tremor Other Hyperkinet Mov (N Y) 3 , doi:10.7916/d89p30bb (2013). Eliasen, E. H., Ferrer, M., Gaini, S., Louis, E. D. & Petersen, M. S. Prevalence of Essential Tremor in the Faroe Islands: A Population-Based Study. Neuroepidemiology 52 , 227-236, doi:10.1159/000499070 (2019). Larsson, T. & Sjogren, T. Essential tremor: a clinical and genetic population study. Acta Psychiatr Scand Suppl 36 , 1-176 (1960). Aharon-Peretz, J., Badarny, S., Ibrahim, R., Gershoni-Baruch, R. & Hassoun, G. Essential Tremor Prevalence is Low in the Druze Population in Northern Israel. Tremor Other Hyperkinet Mov (N Y) 2 , doi:10.7916/d8gf0s7h (2012). https://www.ksh.hu/nepszamlalas/reszletes_tablak accessed on the 10th of Febrary 2025. https://ec.europa.eu/eurostat/web/products-manuals-and-guidelines/-/ks-ra-13-028 last accessed on the 10 of February, 2025. https://nepszamlalas2022.ksh.hu/ last accessed on the 10th of February, 2025. Benito-León, J., Bermejo-Pareja, F., Morales, J. M., Vega, S. & Molina, J. A. Prevalence of essential tremor in three elderly populations of central Spain. Mov Disord 18 , 389-394, doi:10.1002/mds.10376 (2003). Bergareche, A. et al. Prevalence of essential tremor: a door-to-door survey in bidasoa, spain. Neuroepidemiology 20 , 125-128, doi:10.1159/000054771 (2001). Crawford, P. & Zimmerman, E. E. Tremor: Sorting Through the Differential Diagnosis. Am Fam Physician 97 , 180-186 (2018). Amlang, C. J., Trujillo Diaz, D. & Louis, E. D. Essential Tremor as a "Waste Basket" Diagnosis: Diagnosing Essential Tremor Remains a Challenge. Front Neurol 11 , 172, doi:10.3389/fneur.2020.00172 (2020). Jain, S., Lo, S. E. & Louis, E. D. Common misdiagnosis of a common neurological disorder: how are we misdiagnosing essential tremor? Arch Neurol 63 , 1100-1104, doi:10.1001/archneur.63.8.1100 (2006). Schrag, A. et al. Widening the Spectrum of Risk Factors, Comorbidities, and Prodromal Features of Parkinson Disease. JAMA Neurol 80 , 161-171, doi:10.1001/jamaneurol.2022.3902 (2023). Sharma, S. & Pandey, S. Approach to a tremor patient. Ann Indian Acad Neurol 19 , 433-443, doi:10.4103/0972-2327.194409 (2016). Tasks of the National Health Insurance Fund of Hungary (Hungarian acronym: NEAK) https://www.neak.gov.hu/oldalak/nyelvi-oldalak/english (accessed 02 May 2025). Szigeti, S., Evetovits, T., Kutzin, J. & Gaál, P. Tax-funded social health insurance: an analysis of revenue sources, Hungary. Bull World Health Organ 97 , 335-348, doi:10.2471/blt.18.218982 (2019). OECD/European Observatory on Health Systems and Policies (2024), Magyarország: Egészségügyi országprofil 2023, OECD Publishing, Paris, https://doi.org/10.1787/5adc0e05-hu. Váradi (2023). A magánfinanszírozás múltja, jelene és jövője Magyarországon. IME Innováció Menedzsment Egészségügy, 22(2), 6-15. https://doi.org/10.53020/IME-2023-201. Folytatódik a magánegészségügy térnyerése, Avaliable from: https://www.nn.hu/sajto/-/content/M5mewRibyh3R/2024-04-16-folytatodik-a-maganegeszsegugy-ternyerese (accessed 04 May 2025). Hayes, M. T. Parkinson's Disease and Parkinsonism. Am J Med 132 , 802-807, doi:10.1016/j.amjmed.2019.03.001 (2019). Louis, E. D., Ottman, R. & Hauser, W. A. How common is the most common adult movement disorder? estimates of the prevalence of essential tremor throughout the world. Mov Disord 13 , 5-10, doi:10.1002/mds.870130105 (1998). Louis, E. D. & Ferreira, J. J. How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Mov Disord 25 , 534-541, doi:10.1002/mds.22838 (2010). Song, P. et al. The global prevalence of essential tremor, with emphasis on age and sex: A meta-analysis. J Glob Health 11 , 04028, doi:10.7189/jogh.11.04028 (2021). Li, S. C. et al. A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China. Arch Neurol 42 , 655-657, doi:10.1001/archneur.1985.04060070045013 (1985). Gerbasi, M. E., Eldar-Lissai, A. & Lyons, K. E. Epidemiology of Pediatric Essential Tremor in the United States: A Systematic Literature Review from 2010 to 2020. Tremor Other Hyperkinet Mov (N Y) 12 , 11, doi:10.5334/tohm.681 (2022). Erro, R. et al. Clinical correlates of "pure" essential tremor: the TITAN study. Front Neurol 14 , 1233524, doi:10.3389/fneur.2023.1233524 (2023). Inzelberg, R. et al. Essential tremor prevalence is low in Arabic villages in Israel: door-to-door neurological examinations. J Neurol 253 , 1557-1560, doi:10.1007/s00415-006-0253-5 (2006). Okubadejo, N. U., Bankole, I. A., Ojo, O. O., Ojini, F. I. & Danesi, M. A. Prevalence of essential tremor in urban Lagos, Nigeria: a door-to-door community-based study. BMC Neurol 12 , 110, doi:10.1186/1471-2377-12-110 (2012). Dotchin, C. L. & Walker, R. W. The prevalence of essential tremor in rural northern Tanzania. J Neurol Neurosurg Psychiatry 79 , 1107-1109, doi:10.1136/jnnp.2007.134304 (2008). Hornabrook, R. W. & Nagurney, J. T. Essential tremor in Papua, New Guinea. Brain 99 , 659-672, doi:10.1093/brain/99.4.659 (1976). Vetterick, C., Lyons, K. E., Matthews, L. G., Pendal, R. & Ravina, B. The Hidden Burden of Disease and Treatment Experiences of Patients with Essential Tremor: A Retrospective Claims Data Analysis. Adv Ther 39 , 5546-5567, doi:10.1007/s12325-022-02318-8 (2022). Louis, E. D., Rohl, B. & Rice, C. Defining the Treatment Gap: What Essential Tremor Patients Want That They Are Not Getting. Tremor Other Hyperkinet Mov (N Y) 5 , 331, doi:10.7916/d87080m9 (2015). Lyons, K. E. & Pahwa, R. Pharmacotherapy of essential tremor : an overview of existing and upcoming agents. CNS Drugs 22 , 1037-1045, doi:10.2165/0023210-200822120-00006 (2008). Lenka, A. & Louis, E. D. Primidone Intolerance in Essential tremor: Is it More than Just Age? Tremor Other Hyperkinet Mov (N Y) 11 , 57, doi:10.5334/tohm.672 (2021). Ait-Daoud, N., Hamby, A. S., Sharma, S. & Blevins, D. A Review of Alprazolam Use, Misuse, and Withdrawal. J Addict Med 12 , 4-10, doi:10.1097/adm.0000000000000350 (2018). Kapinos, K. A. & Louis, E. D. Prescription Drug Utilization among Patients with Essential Tremor: A Cross-Sectional Study of More Than 36,000 Patients. Mov Disord Clin Pract 11 , 1203-1211, doi:10.1002/mdc3.14155 (2024). Shah, C., Jackson, G. R., Sarwar, A. I., Mandava, P. & Jamal, F. Treatment Patterns in Essential Tremor: A Retrospective Analysis. Tremor Other Hyperkinet Mov (N Y) 12 , 10, doi:10.5334/tohm.682 (2022). Ma, T. T. et al. Global trends in the consumption of benzodiazepines and Z-drugs in 67 countries and regions from 2008 to 2018: a sales data analysis. Sleep 46 , doi:10.1093/sleep/zsad124 (2023). Lukačišinová, A. et al. Prevalence, country-specific prescribing patterns and determinants of benzodiazepine use in community-residing older adults in 7 European countries. BMC Geriatr 24 , 240, doi:10.1186/s12877-024-04742-7 (2024). Rosman, S., Le Vaillant, M. & Pelletier-Fleury, N. Gaining insight into benzodiazepine prescribing in General Practice in France: a data-based study. BMC Fam Pract 12 , 28, doi:10.1186/1471-2296-12-28 (2011). Barboza Zanetti, M. O. et al. Consumption patterns and factors associated with inappropriate prescribing of benzodiazepines in Primary Health Care settings. PLoS One 19 , e0309984, doi:10.1371/journal.pone.0309984 (2024). Gautam, D. et al. Demographics of focused ultrasound thalamotomy for essential tremor and trends in deep brain stimulation surgery after its introduction in the USA. BMJ Neurol Open 6 , e000582, doi:10.1136/bmjno-2023-000582 (2024). Sarica, C. et al. Trends and disparities in deep brain stimulation utilization in the United States: a Nationwide Inpatient Sample analysis from 1993 to 2017. Lancet Reg Health Am 26 , 100599, doi:10.1016/j.lana.2023.100599 (2023). Bishay, A. E. et al. Global Economic Evaluation of the Reported Costs of Deep Brain Stimulation. Stereotact Funct Neurosurg 102 , 257-274, doi:10.1159/000537865 (2024). Ravikumar, V. K. et al. Cost-effectiveness of focused ultrasound, radiosurgery, and DBS for essential tremor. Mov Disord 32 , 1165-1173, doi:10.1002/mds.26997 (2017). Jameel, A. et al. The cost-effectiveness of unilateral magnetic resonance-guided focused ultrasound in comparison with unilateral deep brain stimulation for the treatment of medically refractory essential tremor in England. Br J Radiol 95 , 20220137, doi:10.1259/bjr.20220137 (2022). Li, C. et al. Cost-Effectiveness of Magnetic Resonance-Guided Focused Ultrasound for Essential Tremor. Mov Disord 34 , 735-743, doi:10.1002/mds.27587 (2019). Deuschl, G., Bain, P. & Brin, M. Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. Mov Disord 13 Suppl 3 , 2-23, doi:10.1002/mds.870131303 (1998). Tables Table 1. Tremor-eliciting conditions and treatments in Group 6 Tremor-eliciting conditions Number (percentage) of patients in Group 6 alcohol abuse 265 (0.65%) hyperthyroidism 242 (0.59%) dystonia 164 (0.4%) multiple sclerosis 137 (0.34%) blepharospasm 119 (0.29%) torticollis 30 (0.07%) Wilson’s disease 14 (0.03%) Tremor-eliciting treatments Number (percentage) of patients in Group 6 amiodarone 1,285 (3.15%) valproate 849 (2.08%) l-thyroxin 403 (1%) lithium 186 (0.45%) We found tremor-eliciting conditions in less than 3% of the patients; none had a frequency higher than 1%. Among the medications that might evoke enhanced physiological tremor, amiodarone was most frequently found, followed by valproate. Table 2. Pharmaceutical and neurosurgical approaches in Group 6 Pharmaceutical therapy Number (percentage) of patients in Group 6 alprazolam 17,911 (44%) propranolol 10,410 (25.57%) clonazepam 6,783 (16.66%) antiparkinsonian medication 6,129 (15.05%) primidone 4,521 (11.1%) topiramate 138 (0.33%) Neurosurgical therapy Number (percentage) of patients in Group 6 deep brain stimulation 157 (0.39%) ablative surgery 33 (0.08%) We show the number and percentage of patients who picked up their prescription of the listed drugs from the pharmacy at least once during the study period. Most patients tried alprazolam, while propranolol was the second most preferred. Topiramate was dispensed to less than 0.5% of the patients. Less than 0.5% of the patients underwent neurosurgery, and the application of deep brain stimulation was almost 5 times as common as that of ablative surgery. Table 3. The use of drug combinations in Group 6 Name of the medications Number (%) of patients taking the combination in Group 6 Time period of medication use (% of the total follow-up time (median and IQR) Medication use in months (median and IQR) propranolol + alprazolam 2,749 (6.75%) 35.13 (13.35-68.12) 30.00 (12.00-57.00) propranolol + clonazepam 1,086 (2.67%) 30.11 (9.34-62.62) 29.45 (9-64.09) primidone + alprazolam 962 (2.36%) 32.63 (11.38-60.26) 30.95 (10.18-57.15) propranolol + primidone 477 (1.17%) 25.78 (7.49-52.52) 29.00 (7.67-58.00) primidone + clonazepam 443 (1.09%) 29.77 (8.99-61.99) 29.00 (10-64.90) propranolol + primidone + alprazolam 182 (0.45%) 16.54 (4.66-36.67) 21.90 (5.62-48.42) propranolol + primidone + clonazepam 138 (0.34%) 17.38 (5.42-41.69) 22.62 (6.31-55.06) topiramate + alprazolam 22 (0.05%) 26.67 (2.87-43.72) 21.97 (3.78-53.32) topiramate + clonazepam 20 (0.05%) 20.89 (5.94-62.00) 26.65 (7.10-54.42) propranolol + topiramate 19 (0.05%) 22.23 (5.96-48.71) 21.23 (4.46-54.16) primidone + topiramate 13 (0.03%) 17.67 (4.48-51.99) 17.90 (4.14-45.73) propranolol + primidone + topiramate 4 (0.01%) 8.50 (1.01-20.30) 10.68 (1.33-31.95) The table presents the number and percentage of patients using the certain drug combination and that how long these patients adhered to it. The most frequently used combination of two medications was propranolol + alprazolam, while propranolol + primidone + alprazolam was the most common triple choice. Table 4. Tendencies for drug switch in Group 4 We looked for patients in the Not Parkinsonian Tremor Group (Group 6), who used antiparkinsonian medication before switching to one of the antitremor medications. Similarly, in case of the patients in the Parkinson’s disease/syndrome group (Group 7), we searched for those, who were first on an antitremor drug, which was later changed to antiparkinsonian medication. From the evaluation of the treatment switches, a small percentage of patients might be misdiagnosed with Parkinson's disease/syndrome or essential tremor. Table 5. Stratified age and gender analysis on the prevalence of essential tremor (Group 8) in Hungary Age of the patients (years) Estimated prevalence of ET among men ( /100.000 citizens) Estimated prevalence of ET among women ( /100.000 citizens) 80 823 768 All 351 394 The highest estimated prevalence was found in the elderly population between 70 and 79 years, followed by the prevalence in people over 80 years and those between 60 and 69 years of age. A slight female predominance exists. Table 6. Prevalence of essential tremor in Europe Country Age (years) Prevalence ( /100.000 citizens) Sample size (number of people) Faroe Island 19 ≥40 3100 1,328 Finland 15 ≥40 550 3,304 Hungary All ages 374 59,676 Italy 16 All ages 405 7,653 Spain 26 ≥65 4800 2000 Spain 25 ≥65 4800 5,278 Spain 18 >65 8420 753 In the table, we present published data from other European countries. Our results are similar to the prevalence data from Italy (405/100,000), but the assessed prevalence in the other studies is substantially higher. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Published Journal Publication published 05 Aug, 2025 Read the published version in Scientific Reports → Version 1 posted Editorial decision: Accepted 22 Jul, 2025 Reviews received at journal 20 Jul, 2025 Reviewers agreed at journal 27 Jun, 2025 Reviews received at journal 25 Jun, 2025 Reviewers agreed at journal 25 Jun, 2025 Reviewers invited by journal 25 Jun, 2025 Submission checks completed at journal 27 May, 2025 First submitted to journal 25 May, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-6140908","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":462421516,"identity":"bd551d56-09c7-4066-90a3-d675cdacb51a","order_by":0,"name":"Andrea Kinga Papp","email":"","orcid":"","institution":"Semmelweis University","correspondingAuthor":false,"prefix":"","firstName":"Andrea","middleName":"Kinga","lastName":"Papp","suffix":""},{"id":462421517,"identity":"7e1c7163-829b-4c74-94e8-edea4719c721","order_by":1,"name":"Ádám József Berki","email":"","orcid":"","institution":"Semmelweis University","correspondingAuthor":false,"prefix":"","firstName":"Ádám","middleName":"József","lastName":"Berki","suffix":""},{"id":462421518,"identity":"b046dd20-ed6e-4966-8033-089f4e00cdcf","order_by":2,"name":"Péter Vinnai","email":"","orcid":"","institution":"HUN-REN SU Neuroepidemiological Research Group","correspondingAuthor":false,"prefix":"","firstName":"Péter","middleName":"","lastName":"Vinnai","suffix":""},{"id":462421519,"identity":"f58cfe44-e9eb-4133-a93d-f187c29fadc8","order_by":3,"name":"András Ajtay","email":"","orcid":"","institution":"Semmelweis University","correspondingAuthor":false,"prefix":"","firstName":"András","middleName":"","lastName":"Ajtay","suffix":""},{"id":462421520,"identity":"6452f8e7-4c0c-4430-82e9-452681479200","order_by":4,"name":"Dániel Bereczki","email":"","orcid":"","institution":"Semmelweis University","correspondingAuthor":false,"prefix":"","firstName":"Dániel","middleName":"","lastName":"Bereczki","suffix":""},{"id":462421521,"identity":"0377d754-a947-413e-add7-59fb0bf2ba61","order_by":5,"name":"Loránd Erőss","email":"","orcid":"","institution":"Semmelweis University","correspondingAuthor":false,"prefix":"","firstName":"Loránd","middleName":"","lastName":"Erőss","suffix":""},{"id":462421522,"identity":"74ce8040-e2f5-4587-8f6a-5060a79eb914","order_by":6,"name":"Gertrúd Tamás","email":"data:image/png;base64,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","orcid":"","institution":"Semmelweis University","correspondingAuthor":true,"prefix":"","firstName":"Gertrúd","middleName":"","lastName":"Tamás","suffix":""}],"badges":[],"createdAt":"2025-03-02 18:53:10","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-6140908/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-6140908/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1038/s41598-025-13145-6","type":"published","date":"2025-08-05T15:57:01+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":83915946,"identity":"db2aa9ad-4888-4060-b681-35c8816b1f03","added_by":"auto","created_at":"2025-06-04 12:41:59","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":474561,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eFlowchart of the selection process\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe flowchart diagram shows the steps of selection from our initial database to the final established number of patients with essential tremor. We excluded the patients represented in the colored boxes from the study. Patients represented in the black box had no pharmacy records (Group 3); in the gray box, they had less than two years of follow-up time (Group 5). Patients depicted in the blue box were considered to have Parkinson’s disease/syndrome (Group 7). The remaining Not Parkinsonian Tremor Group contained data from 40,712 patients (Group 6). After ruling out people with possible Essential tremor plus syndromes and other tremor-eliciting conditions and treatments (Group 9), the estimated number of patients with essential tremor was 37,249 (Group 8).\u003c/p\u003e","description":"","filename":"Figure1.png","url":"https://assets-eu.researchsquare.com/files/rs-6140908/v1/67b3b3454a8aef3cb673fdeb.png"},{"id":83914582,"identity":"f60a073b-db07-4e7f-9bc9-ea5655103cc4","added_by":"auto","created_at":"2025-06-04 12:33:59","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":1159752,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eCustoms of medication refills in the Not Parkinsonian Tremor Group (Group 6)\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eDuring our investigation period, 14,825 patients did not try any studied medication. Most of those being on pharmacotherapy picked up the prescription of alprazolam one or more times. The ratio of those who refilled the respective medication more than once compared to those who asked for it only once at the pharmacy, as a metric of adherence, was the highest for alprazolam. Only 138 patients used topiramate.\u003c/p\u003e","description":"","filename":"Figure2.png","url":"https://assets-eu.researchsquare.com/files/rs-6140908/v1/69d22e45eac671590ac0a36b.png"},{"id":83914584,"identity":"9ae60823-43e5-419b-a702-a5edde30e4e1","added_by":"auto","created_at":"2025-06-04 12:33:59","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":1733352,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eThe number of patients in Group 6 using the represented antitremor drug for the most extended period of time\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eEach column represents the number of patients who refilled a particular medication most prolongedly out of the five studied ones during our observation period. Most patients opted for alprazolam for the most extended period of time.\u003c/p\u003e","description":"","filename":"Figure3.png","url":"https://assets-eu.researchsquare.com/files/rs-6140908/v1/6599bf3b98a62cdaedb6bdaa.png"},{"id":83916413,"identity":"e3913ec9-9f16-450e-939c-6ed63a6bb046","added_by":"auto","created_at":"2025-06-04 12:50:00","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":1016525,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eThe lengths of the medication use in Group 6\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe plot shows the time period in months when the patients refilled the listed drugs from the pharmacy. The duration of medication uses significantly differed (p\u003cem\u003e\u003cstrong\u003e\u0026lt;\u003c/strong\u003e\u003c/em\u003e0.0001, Kruskal-Wallis test), being the longest for alprazolam and the shortest for topiramate. Post hoc Dunn's test showed that the difference was significant between each medication (p\u003cem\u003e\u003cstrong\u003e\u0026lt;\u003c/strong\u003e\u003c/em\u003e0.05), except for the comparison between propranolol and primidone (p\u0026gt;0.05; NS).\u003c/p\u003e","description":"","filename":"Figure4.png","url":"https://assets-eu.researchsquare.com/files/rs-6140908/v1/6d7af800a50d0d039c971890.png"},{"id":88814848,"identity":"f96ab01e-9116-4197-b615-88ffc658b327","added_by":"auto","created_at":"2025-08-11 16:10:08","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":4388509,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-6140908/v1/5e1d59df-8994-4a05-94b2-9aa5755efb86.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Prevalence estimation of essential tremor in Hungary between 2010 and 2020 based on the National Health Insurance Fund database","fulltext":[{"header":"Introduction","content":"\u003cp\u003eEssential tremor (ET) is an isolated tremor syndrome of bilateral upper limb postural or kinetic tremor, sometimes accompanied by head tremor or tremor in other body parts\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u003c/sup\u003e. Its differential diagnosis is often a challenge. Essential tremor associated with soft neurological signs, such as impaired tandem gait, mild memory impairment, or subtle dystonic posturing, is labeled essential tremor plus (ET plus) syndrome. Tremor appears in several neurodegenerative, mitochondrial, infectious, endocrine, or metabolic disorders, or it is evoked by some frequently administered drugs or toxins\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u003c/sup\u003e. In the early stages of Parkinson\u0026rsquo;s disease, essential tremor is the most common misdiagnosis\u003csup\u003e\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eAlthough essential tremor is a benign disorder, it can substantially decrease the quality of life\u003csup\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e, as many patients experience a regular and consistent worsening in their condition\u003csup\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u003c/sup\u003e. Furthermore, many patients feel hopeless in coping with their illness; demoralization was found to be nearly as frequent in essential tremor as in chronic or terminal diseases, such as in cancer, coronary heart disease, or Parkinson\u0026rsquo;s disease\u003csup\u003e\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e\u003c/sup\u003e, highlighting the need to discover local therapeutic habits in this patient population.\u003c/p\u003e \u003cp\u003eIn evidence-based recommendations, propranolol, primidone, and topiramate (in a daily dose higher than 200 mg) were categorized as clinically useful, while alprazolam as possibly useful in ET\u003csup\u003e\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e,\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/sup\u003e. Propranolol and primidone are frequently administered in combination because they synergize\u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e. Botulinum toxin A may have a beneficial effect in selected cases\u003csup\u003e\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e. Unilateral stimulation of the ventral intermedial nucleus of the thalamus, unilateral focused ultrasound thalamotomy, as well as radiofrequency thalamotomy, are possibly effective in essential tremor with acceptable risks, according to the latest guideline\u003csup\u003e\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e. Bilateral neurosurgical procedures are still under investigation for creating evidence-based recommendations on their use; however, according to expert opinion, similarly to unilateral surgery, they offer better outcomes (with an estimated improvement of around 80%) than medication therapies\u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eEssential tremor is considered to be one of the most common movement disorders in adults; it is up to 4\u0026ndash;5 times more common than Parkinson\u0026rsquo;s disease in previously published studies\u003csup\u003e\u003cspan additionalcitationids=\"CR11\" citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e\u003c/sup\u003e. Its prevalence after the age of 65 years is close to that of Alzheimer\u0026rsquo;s disease\u003csup\u003e\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u003c/sup\u003e. There is remarkably less epidemiological data from Europe than from the Asian continent\u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003e. The prevalence of essential tremor has been studied in only a few European countries (Finland\u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e, Italy\u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e,\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e, Spain\u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e, Faroe Islands\u003csup\u003e\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e) and not in the Central European regions; the prevalence of ET in these countries ranges from 0.4%\u003csup\u003e16\u003c/sup\u003e to 1.4% in the general population\u003csup\u003e\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/sup\u003e and up to 8.6% in people over 65 years\u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e. Some population-based studies investigate only small geographical territories\u003csup\u003e\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e,\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003e In this study, we aimed to calculate the ET prevalence in Hungary, despite the difficulties of its differential diagnosis; and to analyze the use of available therapeutic approaches recommended by international guidelines. We wanted to explore the necessary public health resources and the nationally unmet challenges for preparing public health actions\u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003e to optimize the care of ET.\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003e\u003cstrong\u003eGrouping the multiple causes of tremor\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eFigure 1 depicts the flowchart of the patient selection. \u0026nbsp;We found 76,631 patients (Group 1) who received any of the four specified tremor ICD-codes between 2004 and 2020 (the mean age at the first tremor diagnosis was 57.45\u0026plusmn;23.14 years, 45.51% male). Due to the limited access to the pharmacy database of medication refills (2010-2020), we excluded 16,955 patients (Group 3) who only received tremor codes between 2004 and 2009. There were 7,317 patients included in the study who not only had their first tremor diagnosis between 2004 and 2009, but also had tremor ICD-codes between 2010 and 2020. Finally, we analyzed 59,676 patients (Group 2) who received tremor codes during our actual study period between 2010 and 2020.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eWe excluded 13,758 patients (Group 5) from the analysis for lack of a sufficient two years\u0026rsquo; follow-up period. There were 45,918 patients (Group 4) with a minimum of two years of observation time; they were further investigated regarding medication use and differential diagnosis. A group of 5,206 patients (Group 7) used antiparkinsonian medications in at least 80% of the study period, starting after the initial 2 years following their first tremor diagnosis; this group of patients was considered to have Parkinson\u0026rsquo;s disease/syndrome and thus were separated from the Not Parkinsonian Tremor Group (Group 6).\u003c/p\u003e\n\u003cp\u003eIn the Not Parkinsonian Tremor Group, we explored the likelihood of each alternative diagnosis outside Parkinsonian syndromes and additional signs associated with tremor, which was less than 1% (Table 1). In the Not Parkinsonian Tremor Group, the ratio of patients taking amiodarone, valproate, and l-thyroxin varied between 1-3%; the ratio was lower for lithium (Table 1).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eOverall, 3,463 patients (Group 9) had at least one alternative or additional diagnosis/sign and/or had consumed at least one of the potentially tremor-inducing medications. In the case of 37,249 patients (Group 8), these methods excluded alternative causes of tremor, so they were considered to have most probably essential tremor.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTherapeutic approaches\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eRegarding pharmacological approaches, we found that in the Not Parkinsonian Tremor Group (Group 6), 14,825 patients (36.41%) never tried any of the five studied medications (propranolol, primidone, topiramate, alprazolam, and clonazepam). A group of 7,459 patients (18.32%) consumed any of these medicines in less than 20% of the follow-up period. Based on this data, 22,284 patients (54.73%)\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003edid not consume any specific medication in at least 80% of the investigated time interval. Alprazolam was dispensed to 44% of those patients who were taking any of the studied medications. (Figure 2). Furthermore, Table 2 shows that among medications taken at least once during the study period, the highest percentage of patients preferred benzodiazepines. Among the five studied antitremor medications, 11,943 patients utilized alprazolam for the longest period of time (Figure 3). The duration of medication use, when the patients refilled the listed drugs from the pharmacy, differed significantly (p\u003cstrong\u003e\u003cem\u003e\u0026lt;\u003c/em\u003e\u003c/strong\u003e0.0001), the longest being for alprazolam and the shortest for topiramate. Post hoc tests showed that the difference was significant\u0026nbsp;between each medication (p\u003cstrong\u003e\u003cem\u003e\u0026lt;\u003c/em\u003e\u003c/strong\u003e0.05), except for the comparison between propranolol and primidone (p\u0026gt;0.05) (Figure 4).\u003c/p\u003e\n\u003cp\u003eWhen the pharmaceutical options were combined, the alprazolam - propranolol therapy was the most common (Table 3).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eLess than 0.5% of the patients underwent neurosurgical procedures such as deep brain stimulation or ablative surgery\u0026nbsp;(Table 2).\u003c/p\u003e\n\u003cp\u003eIn relation to the total number of patients in the Parkinson\u0026apos;s tremor and Not Parkinsonian Tremor Group, less than 4% of patients were later switched from antiparkinsonian therapy to other antitremor therapy, while less than 3% were initially on other anti-tremor drugs that were later changed to antiparkinsonian drugs (Table 4).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePrevalence of essential tremor\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eOur methods identified 37,429 patients with essential tremor (mean age at first tremor diagnosis: 54.93 \u0026plusmn; 23.4 years, 44.73% male). Using the population data from the 2011 Census in Hungary\u003csup\u003e22\u003c/sup\u003e, the estimated period prevalence of the disease was 374/100,000. The age-standardized period prevalence of essential tremor for the European Standard Population of 2013\u003csup\u003e23\u003c/sup\u003e was 388/100,000. If we utilize the results from the Hungarian Census in 2022\u003csup\u003e24\u003c/sup\u003e, the period prevalence of essential tremor was 387/100,000 in Hungary; when standardizing it to the European Standard Population of 2013, it was 378/100,000.\u003c/p\u003e\n\u003cp\u003eThe stratified age and gender analysis in the Probably Essential Tremor Group (Group 8) showed the highest prevalence in the elderly population (1.29 % among men and 1.25% among women aged 70-79), the prevalence was similarly high in people over 80 years (0.82% in men and 0.79% among women) and those between 60 and 69 years of age (0.74% for both gender groups). When evaluating by gender, the overall prevalence was 0.35% among men (0.39%) and women (Table 5).\u003c/p\u003e\n\u003cp\u003eWhen compared to data from other European countries, the estimated prevalence of essential tremor in Hungary is similar to the one assessed in Italy (405/100,000)\u003csup\u003e16\u003c/sup\u003e but lower than in the Faroe Island\u003csup\u003e19\u003c/sup\u003e, Finland\u003csup\u003e15\u003c/sup\u003e, and Spain\u003csup\u003e18,25,26\u003c/sup\u003e (Table 6). \u0026nbsp;\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eIn this study, we found that the period prevalence of essential tremor standardized to the European Standard Population was approximately 0.378\u0026ndash;0.388% between 2010 and 2020 in Hungary. Alprazolam followed by propranolol were chosen for the longest time period by most of the patients. The propranolol-alprazolam combination was taken in the highest percentage of the medication period by most of the patients. Among neurosurgical procedures deep brain stimulation and ablative surgery were applied in less than 0.5% of the patients, with a possible diagnosis of essential tremor.\u003c/p\u003e \u003cp\u003eRecognition of essential tremor in a broad national health insurance fund database is challenging as standard tests do not support the differential diagnosis processes, which rely on clinical observation\u003csup\u003e\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u003c/sup\u003e. Misdiagnosis is more likely to occur when its severity is subtle\u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u003c/sup\u003e. Some studies indicate that the diagnosis of essential tremor is over-applied, with many of the patients having other movement disorders, most commonly Parkinson\u0026rsquo;s disease or dystonia\u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e,\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u003c/sup\u003e. Tremor is indeed described as a common prodromal presentation of Parkinson\u0026rsquo;s disease\u003csup\u003e\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u003c/sup\u003e. Physiological tremor is also among the most common alternative diagnoses\u003csup\u003e\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e\u003c/sup\u003e. Thus, we have attempted to narrow down the population of patients with tremor to essential tremor, based on co-diagnoses and medication use data.\u003c/p\u003e \u003cp\u003eThe Hungarian healthcare system has a single health insurance fund managed by the Health Insurance Fund Management Agency (NHIF)\u003csup\u003e\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e\u003c/sup\u003e. Every Hungarian citizen has a personal identifier\u003csup\u003e\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e\u003c/sup\u003e, and all their medical records from hospitals and outpatient services are linked to this identifier and recorded in the database we used.\u003c/p\u003e \u003cp\u003eState health expenditure in relation to GDP in 2021 was 7.4% in Hungary compared to 11% of the EU average\u003csup\u003e\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e\u003c/sup\u003e. Between 2000 and 2018, 25\u0026ndash;30% of the healthcare expenditure was financed by individuals and private companies\u003csup\u003e\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e\u003c/sup\u003e, but detailed data on each field of the private medical system is scarce. An available survey from Hungary, in which 1100 people were asked, found that among those who sought private medical help, 3% chose neurology\u003csup\u003e\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e\u003c/sup\u003e. If we extrapolate this finding, excluding private healthcare would introduce only an approximately 1% (30% x 3%) bias in our findings.\u003c/p\u003e \u003cp\u003eIn the study period, we initially had 59,676 patients with tremor ICD-10 (International Classification of Diseases-10) codes. Since a short observation time increases the likelihood of misdiagnosis\u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u003c/sup\u003e, we excluded patients with less than two years follow-up period from further analysis. As the next step, we endeavored to screen out patients with Parkinson\u0026rsquo;s disease, trusting in their need for continuous medication use, which may be initiated after the first years from symptom onset in agreement with the patient\u003csup\u003e\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e\u003c/sup\u003e. When the patient took antiparkinsonian medication in at least 80% of the total follow-up time, excluding the initial two years, the patient was considered to have Parkinson\u0026rsquo;s disease/syndrome.\u003c/p\u003e \u003cp\u003eIn the remaining Not Parkinsonian Tremor Group, we sorted out patients with alternative causes and co-existing symptoms and tremor-inducing/intensifying medication therapy. Among the conditions, alcohol abuse and hyperthyroidism, among the medications, amiodarone was the most commonly found factor. We saw at least one provoking condition or medication in approximately 9% of the cases. Even though the use of tremor-evoking/enhancing medications does not preclude an underlying essential tremor, we separated this small group of patients to get an estimate that was as accurate as we could ascertain. Finally, we were left with 37,249 people with most probably essential tremor.\u003c/p\u003e \u003cp\u003eThere is a marked heterogeneity in prevalence estimates in essential tremor, ranging from 0.01\u0026ndash;20%, greater than that reported for many other neurological diseases\u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003e. A systematic review published in 1998 concluded that the prevalence of essential tremor might range from 0.4 to 3.92% across different populations. However, no meta-analysis could be performed on this data because of the disparate methodologies\u003csup\u003e\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e\u003c/sup\u003e. There are three published meta-analyses on essential tremor prevalence\u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e,\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e,\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e\u003c/sup\u003e. In the first one from 2010\u003csup\u003e39\u003c/sup\u003e, the overall prevalence of 28 population-based studies was 0.9% (all ages, limited external validity); in an additional descriptive review of two studies (reported about the patient examination and sensitivity of the methods), the prevalence was 0.4% (all ages). Since more population-based prevalence data became available, the same group conducted another meta-analysis in 2021\u003csup\u003e14\u003c/sup\u003e. Based on 42 studies, they reported a pooled prevalence of 1.33% of the disease (all ages)\u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003e. A descriptive analytical approach of three studies (reported about the patient examination and sensitivity of the methods) revealed that the median prevalence of essential tremor was 0.4%, and the mean was 0.67% (all ages)\u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003e. Another meta-analysis from 2021 based on 29 population-based studies reported a prevalence of 0.32% (all ages)\u003csup\u003e\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e\u003c/sup\u003e, which is comparable to our findings.\u003c/p\u003e \u003cp\u003eDirect comparison of prevalence data in the different meta-analyses is not possible because the proportion of studies conducted in middle-aged (\u0026ge;\u0026thinsp;40 years) or elderly (\u0026ge;\u0026thinsp;60 or \u0026ge;\u0026thinsp;65 years) populations vary, influencing the results as the prevalence is known to increase with age\u003csup\u003e\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eHowever, the estimated prevalence of essential tremor is highly heterogeneous\u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003e; it ranges from 0.01%\u003csup\u003e41\u003c/sup\u003e to 20%\u003csup\u003e11\u003c/sup\u003e, behind which there may be several factors. Even though essential tremor can also be present in the pediatric population\u003csup\u003e\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e\u003c/sup\u003e, many of the population-based prevalence studies only investigate older people\u003csup\u003e\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e,\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e,\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u003c/sup\u003e. However, the age of onset has two peaks: the smaller proportion of young onset cases culminated in their twenties and a more prominent peak given by the sporadic cases starting above 60 years of age\u003csup\u003e\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e\u003c/sup\u003e. Essential tremor becomes more common with advanced age: the prevalence was indeed shown to increase by 74% for every decade increase in age\u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003e. The estimated prevalence of essential tremor among the elderly, aged 60 or older, ranges from 0.5%\u003csup\u003e44\u003c/sup\u003e to 26.1%\u003csup\u003e45\u003c/sup\u003e. A study analyzing a community in Nigeria found a 42.9% prevalence of ET in people aged 85 or older\u003csup\u003e\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e\u003c/sup\u003e. Males were more likely to be affected than females in many studies\u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e,\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e,\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e\u003c/sup\u003e, however the opposite tendency was also reported\u003csup\u003e\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e\u003c/sup\u003e, other studies found no gender differences in disease distribution\u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003e. However, the heterogeneity in prevalence data could not be explained by stratifying the data by age and gender\u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eWhen interpreting the results from other European countries, it is important to note that most of the data represent small geographical territories of each country\u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e,\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e,\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e,\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e,\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e and investigate only older people population\u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e,\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e,\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e, where the prevalence is known to be higher\u003csup\u003e\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e\u003c/sup\u003e. Only in Italy\u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u003c/sup\u003e was the study conducted on all age groups, and the results are similar to ours. None of the other studies analyzed therapeutic trends.\u003c/p\u003e \u003cp\u003eOur results regarding the stratification analysis on age are congruent with the literature since the prevalence of essential tremor is higher in the elderly\u003csup\u003e\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e\u003c/sup\u003e. The prevalence of the disease is generally higher in males\u003csup\u003e\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e\u003c/sup\u003e, but other studies have also found a slight female predominance\u003csup\u003e\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e,\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eThe mild symptoms of essential tremor may not require any treatment, and the pharmacological management of severe essential tremor is limited\u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e. Our study found that over one-third of the patients never tried any of the five studied medications (i.e., propranolol, primidone, topiramate, alprazolam, and clonazepam). More than 50% of the patients did not consume these medications in 80% of the follow-up period.\u003c/p\u003e \u003cp\u003eThe most commonly used drug was alprazolam, followed by propranolol and clonazepam. Only a small proportion of patients consumed primidone, and less than 0.5% took topiramate.\u003c/p\u003e \u003cp\u003eThe effect of the therapies above (with an average improvement of 60%) is limited\u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/sup\u003e, which, together with the side effects, the younger age of the patients, and more severe depression, may result in non-adherence\u003csup\u003e\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e\u003c/sup\u003e. Adherence to any medication is influenced by the effect of the drug on the symptom, its likely unpleasant side effects, and any possible comorbid effects\u003csup\u003e\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e,\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e\u003c/sup\u003e. We defined it with two measures in our study. First, with the number of patients to whom the given drug was dispensed at least once. Alprazolam was frequently refilled by the highest percentage of patients, which might be influenced by its anxiolytic effect\u003csup\u003e\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e\u003c/sup\u003e. A study conducted in the US found that 1\u0026ndash;2% of the general population uses alprazolam\u003csup\u003e\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e\u003c/sup\u003e. This drug was taken by 44% of our Not Parkinsonian Tremor Group (Group 6) patient population, which, might not be attributed to its anti-anxiety effect alone. The second metric of medication adherence we investigated is how many patients refilled a particular drug for the most prolonged period of time. Alprazolam was taken for the longest time by the most patients, followed by propranolol, clonazepam, primidone, and topiramate. In our patient database, the combination of propranolol and alprazolam was the most preferred. The availability of medicines also influences medication habits. In Hungary, benzodiazepine preparations and propranolol can be prescribed by a general practitioner. In contrast, primidone can only be prescribed by a neurologist, and topiramate can be prescribed or authorized for up to one year by a neurologist. Botulinum toxin type A injection has an off-label indication in essential tremor\u003csup\u003e\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e; it is not covered by the national health insurance fund and hence was missing in the therapeutic approaches in our study.\u003c/p\u003e \u003cp\u003eThe widespread use of alprazolam might be associated with psychiatric comorbidities and the probably inappropriate prescription of the drug by physicians.\u003c/p\u003e \u003cp\u003eA large retrospective study containing data from more than 120 thousand ET patients from the USA assessed the prevalence of comorbidities among the patients and found that 29% of them had an anxiety disorder, and depression was even more common (44%). They found that in 2019, benzodiazepines were only prescribed to 19% of the essential tremor patients\u003csup\u003e\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e\u003c/sup\u003e. Even if we extrapolate this finding, the proportion of patients with anxiety would still not fully explain the much higher percentage (44%) of our patients taking alprazolam. Therefore, other factors contribute to it as well. Studies on the rate of the population using benzodiazepines in Hungary have not been conducted yet.\u003c/p\u003e \u003cp\u003eA cross-sectional study from the US analyzing drug utilization among more than 36,000 ET patients found that 17% had at least one prescription for a benzodiazepine\u003csup\u003e\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e\u003c/sup\u003e. A smaller study of 1,074 ET patients in the US reported that only 2% of the drug prescriptions were for benzodiazepines, specifically clonazepam and diazepam; alprazolam was not studied\u003csup\u003e\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eA study investigating the global use of benzodiazepines (namely the defined daily dose (DDD) per 1000 inhabitants per day) found that this metric is more than twice as high in Hungary compared to the average worldwide consumption; however, the study does not contain data on the percentage of the population or the exact number of people taking these drugs\u003csup\u003e\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eRegarding the European population, a cross-sectional study conducted in 2019\u0026ndash;2020 in seven European countries (Czech Republic, Serbia, Estonia, Bulgaria, Croatia, Turkey, and Spain) found that 14.9% of the investigated older adults (aged 65 or older) were benzodiazepine users, in Croatia, Spain, and Serbia the proportion was more than 30%\u003csup\u003e56\u003c/sup\u003e. In France, benzodiazepines were prescribed to 12.5% of the adult population\u003csup\u003e\u003cspan citationid=\"CR57\" class=\"CitationRef\"\u003e57\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eIt was revealed in Brazil that primary health care is the most significant source of benzodiazepine prescription, which is frequently inappropriate\u003csup\u003e\u003cspan citationid=\"CR58\" class=\"CitationRef\"\u003e58\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eFuture research focusing on psychiatric comorbidities among the essential tremor patients in Hungary could explore the cause of high alprazolam consumption in this patient population.\u003c/p\u003e \u003cp\u003eAt the time of the study, a small number of patients had switched from antiparkinsonian therapy to other tremor therapy and vice versa. These results also corroborate the diagnostic difficulties in the first period of the disease\u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e,\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u003c/sup\u003e; however, they were rare in our study.\u003c/p\u003e \u003cp\u003eOur data indicated that during this 11-year long time interval, only a small proportion of the essential tremor patients were operated on: 0.39% of the patients received deep brain stimulation, and the number of those who underwent lesioning/ablative surgery was remarkably lower than that. MRI-guided ultrasound thalamotomy was unavailable in the study period and is still unavailable in Hungary. After its introduction in 2016, there have been an increasing number of MRI-guided ultrasound thalamotomies each year, with almost 2000 procedures in 2022 in the United States\u003csup\u003e\u003cspan citationid=\"CR59\" class=\"CitationRef\"\u003e59\u003c/span\u003e\u003c/sup\u003e. ET represented 24% of all DBS indications in the United States between 1993 and 2017, with 1331 implantations per year\u003csup\u003e\u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e60\u003c/span\u003e\u003c/sup\u003e. According to this published data\u003csup\u003e\u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e60\u003c/span\u003e\u003c/sup\u003e, 2.7 times more DBS procedures were done for ET in the US than in Hungary per unit population in the time interval overlapping with the time of our study. Economic calculations show that the cost of deep brain stimulation is similar in studies performed in different countries from Europe, Asia and North America and between the distinct indications\u003csup\u003e\u003cspan citationid=\"CR61\" class=\"CitationRef\"\u003e61\u003c/span\u003e\u003c/sup\u003e. Magnetic resonance-guided focused ultrasound thalamotomy has a more favourable cost-effectiveness profile than deep brain stimulation in essential tremor\u003csup\u003e\u003cspan additionalcitationids=\"CR63\" citationid=\"CR62\" class=\"CitationRef\"\u003e62\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR64\" class=\"CitationRef\"\u003e64\u003c/span\u003e\u003c/sup\u003e. When comparing focused ultrasound thalamotomy and no surgery in people ineligible for neurosurgical procedures with craniotomy, the former is cost-effective due to improved quality-adjusted life years\u003csup\u003e\u003cspan citationid=\"CR64\" class=\"CitationRef\"\u003e64\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eIn conclusion, Hungary's estimated prevalence of essential tremor is comparable to the global prevalence found in systematic reviews and meta-analyses. On the other hand, the high use of alprazolam and the small number of neurosurgical interventions require improvements in treatment planning at national level.\u003c/p\u003e \u003cp\u003eConsidering the global aging trend, an increase in essential tremor cases can be expected\u003csup\u003e\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e\u003c/sup\u003e. A broader use of neurosurgical interventions and the possible introduction of focused ultrasound therapy is proposed by conducting cost-effectiveness studies and, in parallel, by establishing national therapeutic guidelines and providing education to physicians.\u003c/p\u003e \u003cp\u003eLimitations\u003c/p\u003e \u003cp\u003eThe prevalence of essential tremor may be underestimated as many patients do not consult a doctor with mild symptoms and do not take medication\u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eThe prevalence determined was a rough estimate from the National Health Insurance Fund database based on physicians' coding of tremor diagnoses. Given the large number of patients, reviewing individual medical records was impossible. Nevertheless, we tried to refine it by a matched, parallel analysis of medication use data. We did not consider data from private care because they did not have mandatory reporting before June 01, 2020.\u003c/p\u003e \u003cp\u003eOur database is anonymized, with no personal identifiers. Therefore, we were unable to validate a subset of cases from it. Consequently, we could not determine the exact values for the sensitivity and specificity of our methodology. A few factors could influence sensitivity and specificity, such as the reliance on ICD-codes and medication use and excluding private healthcare (approximately 1% bias).\u003c/p\u003e \u003cp\u003eAnalyzing regional or urban-rural differences in prevalence was impossible because the database does not contain information regarding patients' places of residence. Nevertheless, addressing this question in the future can further characterize the prevalence of essential tremor.\u003c/p\u003e"},{"header":"Methods","content":"\u003cp\u003e\u003cstrong\u003eDescription of databases and identification of tremor patients\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eIn order to estimate the prevalence of essential tremor in Hungary, we used two independent databases: the databases of the National Health Insurance Fund covering patient care from all hospitals and specialist outpatient services (between 2004 and 2020); and the pharmacy database of medication refills from all pharmacies throughout the country (between 2010 and 2020). The original patient identifier codes were anonymized and we used encrypted identifiers. The study was performed according to the Declaration of Helsinki. All personal data protection regulations were followed. The study was approved by the Medical Research Council of Hungary (ETT TUKEB IV/7136- 1 /2021/EKU). Due to the retrospective nature of the study, the Medical Research Council of Hungary waived the need of obtaining informed consent.\u003c/p\u003e\n\u003cp\u003eEach patient had a constant encrypted identifier in the whole study period in the two distinct databases, allowing us to link the matching records. As pharmacy medication refills data were available only from 2010 on, we only analyzed the overlapping 11-year-interval between 2010 and 2020.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eIn the first step we analyzed the inpatient and specialist outpatient databases and selected those who, during these years, received at least once a primary or secondary diagnosis of tremor (Group 2). We considered the reported tremor diagnoses if they were established by neurologists and other specialists. With this selection criterion, we included patients who might have only consulted with their general physician to reduce the possible underrepresentation of mild essential tremor cases. For the diagnosis codes we used the 10\u003csup\u003eth\u003c/sup\u003e Edition of the International Classification of Diseases (ICD-10) and searched for the ICD-codes accordingly: G2500 (essential tremor), G2510 (drug-induced tremor), G2520 (other specified forms of tremor), R2510 (tremor, unspecified).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAs other symptoms of Parkinson\u0026apos;s disease are likely to appear within two years of the onset of monosymptomatic tremor in Parkinson\u0026rsquo;s disease\u003csup\u003e65\u003c/sup\u003e, we restricted the study sample to patients with a documented follow-up period of at least 2 years during the study period (Group 4) to increase the robustness of the diagnosis. If patients died or our study period had come to an end within two years after receiving the first tremor diagnosis, we excluded that data from further analysis (Figure 1).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eGrouping the multiple causes of tremor\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAs the next step, we sorted out patients with Parkinson\u0026rsquo;s disease (Group 7) using the following criteria: the pharmacy records had to indicate that the patient used antiparkinsonian medication in at least 80% of the follow-up time (Anatomical Therapeutic Chemical Classification System - ATC - code: N04). When calculating this ratio, we subtracted two years from the actual follow-up time of the patient because of the uncertainty of the diagnosis of Parkinson\u0026rsquo;s disease, which could lead to alternative treatment strategies. After removing the Parkinson\u0026apos;s patients, the remaining group of patients (Not Parkinsonian Tremor Group: Group 6) was further investigated (Figure 1).\u003c/p\u003e\n\u003cp\u003eIn addition to Parkinson\u0026rsquo;s disease, other diseases or signs might also receive a tremor diagnosis code in the medical records. In Group 6, we searched for the following ICD-10 codes for alternative diagnoses in tremor syndromes: multiple sclerosis (G35H0, G3680, G3690, G3710, G3730, G3780, G3790), hyperthyroidism (E0510, E0530, E0600, E0610, E0620, E0640, E0650, E0690, E0780, E0790), alcohol abuse (F1010, F1020, F1030, F1040, R7800, T5180, T5190, \u0026nbsp;Y9090, Y9100, Y9110, Y9120, Y9130, Y9190, Z7210) and Wilson\u0026rsquo;s disease (E8300)\u0026nbsp;as well as for additional diagnosis or signs that could be associated with tremor: dystonia (G2400, G2410, G2420, G2440, G2480, G2490), torticollis (G2430) and blepharospasm (G2450).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eWe also examined the refills of the following drugs, which may evoke enhanced physiological tremor: amiodarone, valproic acid, l-thyroxin and lithium.\u003c/p\u003e\n\u003cp\u003eWe have performed stratification analysis by gender and age in the Most probably Essential Tremor Group (Group 8, Table 5). \u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTherapeutic approaches\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eIn the Not Parkinsonian Tremor Group (Group 6) we examined the pharmaceutical therapies from a number of different perspectives. Within the pharmacy database, we evaluated the use of the most frequently applied medications: propranolol, primidone, and topiramate for essential tremor, antiparkinsonian medications (ATC N04), and two benzodiazepines (alprazolam and clonazepam). For each drug, we collected the following information: the time of the first and last acquisition of medication during the study period, the interval between them, and the number of medication packages dispensed to the patient.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eWe determined the number of patients to whom none of the selected medicines were dispensed for at least 20% of the study period.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eIf the patients took medication, we observed which drug they preferred for the most prolonged time period.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eWe then calculated the temporal ratio of each medication use individually, dividing the time interval of medication refills by the total follow-up time. We further investigated the drug combinations, the number of patients utilizing the combinations, the length of their utilization time period and the temporal ratio of their use were assessed. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003eFurthermore, we looked into changes in therapy: we assessed the number of patients in Group 6 who first was on antiparkinsonian medications (ATC N04) and later switched to one of the antitremor drugs (propranolol, primidone, and topiramate, alprazolam and clonazepam). Among the patients who were finally considered to have Parkinson\u0026rsquo;s disease/syndrome (Group 7), we selected those who were first on an antitremor medication, and it was later changed to antiparkinsonian therapy.\u003c/p\u003e\n\u003cp\u003eIn addition to medications, we searched the database for surgical procedures, such as ablative surgery and deep brain stimulation.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eStatistical analysis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe estimation of the prevalence of essential tremor in Hungary was based on the Hungarian population data. We calculated the crude period prevalence in Hungary using data from the Central Bureau for Statistics (Census 2011\u003csup\u003e22\u003c/sup\u003e and Census 2022\u003csup\u003e24\u003c/sup\u003e). With the help of the direct standardization method, our results were age-adjusted to the European Standard Population of 2013. We also compared the results with existing prevalence data from other European countries. For data analysis, we used descriptive statistics. Normality was evaluated with Shapiro\u0026ndash;Wilk test. We used OriginLab software (OriginLab Corporation, Northampton, MA, USA) for statistical analysis and data presentation. Krusall-Wallis test (one-way ANOVA on ranks) was used with the post-hoc Dunn\u0026apos;s test to detect possible differences between the durations of medication use.\u0026nbsp;\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eData availability statement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe dataset for this study can be requested from the corresponding author by qualified researchers, in accordance with the limitations set by the ethical approval. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe work was partly supported by grant No.: TKP2021-EGA-25 of the National Research, Development and Innovation Office , Hungary\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA.K.P., A.J.B., P.V., A.A., D.B., L.E., G.T.: data collection, manuscript review, and critique. A.K.P., A.J.B., G.T.: data analysis. A.K.P., A.J.B., D.B., L.E., G.T.: experimental design. A.K.P., A.J.B., G.T.: manuscript writing. All authors have read and approved the final manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAdditional information\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting Interest Statement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors have no competing financial and non-financial interest to declare.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n \u003cli\u003eBhatia, K. P.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e Consensus Statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society. \u003cem\u003eMov Disord\u003c/em\u003e\u003cstrong\u003e33\u003c/strong\u003e, 75-87, doi:10.1002/mds.27121 (2018).\u003c/li\u003e\n \u003cli\u003eTolosa, E., Wenning, G. \u0026amp; Poewe, W. The diagnosis of Parkinson\u0026apos;s disease. \u003cem\u003eLancet Neurol\u003c/em\u003e\u003cstrong\u003e5\u003c/strong\u003e, 75-86, doi:10.1016/s1474-4422(05)70285-4 (2006).\u003c/li\u003e\n \u003cli\u003eLorenz, D., Schwieger, D., Moises, H. \u0026amp; Deuschl, G. Quality of life and personality in essential tremor patients. \u003cem\u003eMov Disord\u003c/em\u003e\u003cstrong\u003e21\u003c/strong\u003e, 1114-1118, doi:10.1002/mds.20884 (2006).\u003c/li\u003e\n \u003cli\u003eGutierrez, J., Park, J., Badejo, O. \u0026amp; Louis, E. D. Worse and Worse and Worse: Essential Tremor Patients\u0026apos; Longitudinal Perspectives on Their Condition. \u003cem\u003eFront Neurol\u003c/em\u003e\u003cstrong\u003e7\u003c/strong\u003e, 175, doi:10.3389/fneur.2016.00175 (2016).\u003c/li\u003e\n \u003cli\u003eCersonsky, T. E. K.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e Demoralization in essential tremor: prevalence, clinical correlates, and dissociation from tremor severity. \u003cem\u003eCNS Spectr\u003c/em\u003e\u003cstrong\u003e25\u003c/strong\u003e, 16-23, doi:10.1017/s1092852918001633 (2020).\u003c/li\u003e\n \u003cli\u003eFerreira, J. J.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e MDS evidence-based review of treatments for essential tremor. \u003cem\u003eMov Disord\u003c/em\u003e\u003cstrong\u003e34\u003c/strong\u003e, 950-958, doi:10.1002/mds.27700 (2019).\u003c/li\u003e\n \u003cli\u003eHopfner, F. \u0026amp; Deuschl, G. Managing Essential Tremor. \u003cem\u003eNeurotherapeutics\u003c/em\u003e\u003cstrong\u003e17\u003c/strong\u003e, 1603-1621, doi:10.1007/s13311-020-00899-2 (2020).\u003c/li\u003e\n \u003cli\u003eSharma, S. \u0026amp; Pandey, S. Treatment of essential tremor: current status. \u003cem\u003ePostgrad Med J\u003c/em\u003e\u003cstrong\u003e96\u003c/strong\u003e, 84-93, doi:10.1136/postgradmedj-2019-136647 (2020).\u003c/li\u003e\n \u003cli\u003eBrin, M. F.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. \u003cem\u003eNeurology\u003c/em\u003e\u003cstrong\u003e56\u003c/strong\u003e, 1523-1528, doi:10.1212/wnl.56.11.1523 (2001).\u003c/li\u003e\n \u003cli\u003eAttia Romdhane, N.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e Prevalence study of neurologic disorders in Kelibia (Tunisia). \u003cem\u003eNeuroepidemiology\u003c/em\u003e\u003cstrong\u003e12\u003c/strong\u003e, 285-299, doi:10.1159/000110330 (1993).\u003c/li\u003e\n \u003cli\u003eKhatter, A. S.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e Prevalence of tremor and Parkinson\u0026apos;s disease. \u003cem\u003eParkinsonism Relat Disord\u003c/em\u003e\u003cstrong\u003e2\u003c/strong\u003e, 205-208, doi:10.1016/s1353-8020(96)00027-2 (1996).\u003c/li\u003e\n \u003cli\u003eMoghal, S., Rajput, A. H., D\u0026apos;Arcy, C. \u0026amp; Rajput, R. Prevalence of movement disorders in elderly community residents. \u003cem\u003eNeuroepidemiology\u003c/em\u003e\u003cstrong\u003e13\u003c/strong\u003e, 175-178, doi:10.1159/000110376 (1994).\u003c/li\u003e\n \u003cli\u003eHirtz, D.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e How common are the \u0026quot;common\u0026quot; neurologic disorders? \u003cem\u003eNeurology\u003c/em\u003e\u003cstrong\u003e68\u003c/strong\u003e, 326-337, doi:10.1212/01.wnl.0000252807.38124.a3 (2007).\u003c/li\u003e\n \u003cli\u003eLouis, E. D. \u0026amp; McCreary, M. How Common is Essential Tremor? Update on the Worldwide Prevalence of Essential Tremor. \u003cem\u003eTremor Other Hyperkinet Mov (N Y)\u003c/em\u003e\u003cstrong\u003e11\u003c/strong\u003e, 28, doi:10.5334/tohm.632 (2021).\u003c/li\u003e\n \u003cli\u003eRautakorpi, I., Takala, J., Marttila, R. J., Sievers, K. \u0026amp; Rinne, U. K. Essential tremor in a Finnish population. \u003cem\u003eActa Neurol Scand\u003c/em\u003e\u003cstrong\u003e66\u003c/strong\u003e, 58-67, doi:10.1111/j.1600-0404.1982.tb03129.x (1982).\u003c/li\u003e\n \u003cli\u003eSalemi, G.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e Prevalence of essential tremor: a door-to-door survey in Terrasini, Sicily. Sicilian Neuro-Epidemiologic Study Group. \u003cem\u003eNeurology\u003c/em\u003e\u003cstrong\u003e44\u003c/strong\u003e, 61-64, doi:10.1212/wnl.44.1.61 (1994).\u003c/li\u003e\n \u003cli\u003eMancini, M. L.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e Prevalence of essential tremor in the territory of Lake Trasimeno, Italy: results of a population-based study. \u003cem\u003eMov Disord\u003c/em\u003e\u003cstrong\u003e22\u003c/strong\u003e, 540-545, doi:10.1002/mds.21349 (2007).\u003c/li\u003e\n \u003cli\u003eSeijo-Mart\u0026iacute;nez, M.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e Prevalence of Essential Tremor on Arosa Island, Spain: a Community-based, Door-to-Door Survey. \u003cem\u003eTremor Other Hyperkinet Mov (N Y)\u003c/em\u003e\u003cstrong\u003e3\u003c/strong\u003e, doi:10.7916/d89p30bb (2013).\u003c/li\u003e\n \u003cli\u003eEliasen, E. H., Ferrer, M., Gaini, S., Louis, E. D. \u0026amp; Petersen, M. S. Prevalence of Essential Tremor in the Faroe Islands: A Population-Based Study. \u003cem\u003eNeuroepidemiology\u003c/em\u003e\u003cstrong\u003e52\u003c/strong\u003e, 227-236, doi:10.1159/000499070 (2019).\u003c/li\u003e\n \u003cli\u003eLarsson, T. \u0026amp; Sjogren, T. Essential tremor: a clinical and genetic population study. \u003cem\u003eActa Psychiatr Scand Suppl\u003c/em\u003e\u003cstrong\u003e36\u003c/strong\u003e, 1-176 (1960).\u003c/li\u003e\n \u003cli\u003eAharon-Peretz, J., Badarny, S., Ibrahim, R., Gershoni-Baruch, R. \u0026amp; Hassoun, G. Essential Tremor Prevalence is Low in the Druze Population in Northern Israel. \u003cem\u003eTremor Other Hyperkinet Mov (N Y)\u003c/em\u003e\u003cstrong\u003e2\u003c/strong\u003e, doi:10.7916/d8gf0s7h (2012).\u003c/li\u003e\n \u003cli\u003ehttps://www.ksh.hu/nepszamlalas/reszletes_tablak accessed on the 10th of Febrary 2025.\u003c/li\u003e\n \u003cli\u003ehttps://ec.europa.eu/eurostat/web/products-manuals-and-guidelines/-/ks-ra-13-028 last accessed on the 10 of February, 2025.\u003c/li\u003e\n \u003cli\u003ehttps://nepszamlalas2022.ksh.hu/ last accessed on the 10th of February, 2025.\u003c/li\u003e\n \u003cli\u003eBenito-Le\u0026oacute;n, J., Bermejo-Pareja, F., Morales, J. M., Vega, S. \u0026amp; Molina, J. A. Prevalence of essential tremor in three elderly populations of central Spain. \u003cem\u003eMov Disord\u003c/em\u003e\u003cstrong\u003e18\u003c/strong\u003e, 389-394, doi:10.1002/mds.10376 (2003).\u003c/li\u003e\n \u003cli\u003eBergareche, A.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e Prevalence of essential tremor: a door-to-door survey in bidasoa, spain. \u003cem\u003eNeuroepidemiology\u003c/em\u003e\u003cstrong\u003e20\u003c/strong\u003e, 125-128, doi:10.1159/000054771 (2001).\u003c/li\u003e\n \u003cli\u003eCrawford, P. \u0026amp; Zimmerman, E. E. Tremor: Sorting Through the Differential Diagnosis. \u003cem\u003eAm Fam Physician\u003c/em\u003e\u003cstrong\u003e97\u003c/strong\u003e, 180-186 (2018).\u003c/li\u003e\n \u003cli\u003eAmlang, C. J., Trujillo Diaz, D. \u0026amp; Louis, E. D. Essential Tremor as a \u0026quot;Waste Basket\u0026quot; Diagnosis: Diagnosing Essential Tremor Remains a Challenge. \u003cem\u003eFront Neurol\u003c/em\u003e\u003cstrong\u003e11\u003c/strong\u003e, 172, doi:10.3389/fneur.2020.00172 (2020).\u003c/li\u003e\n \u003cli\u003eJain, S., Lo, S. E. \u0026amp; Louis, E. D. Common misdiagnosis of a common neurological disorder: how are we misdiagnosing essential tremor? \u003cem\u003eArch Neurol\u003c/em\u003e\u003cstrong\u003e63\u003c/strong\u003e, 1100-1104, doi:10.1001/archneur.63.8.1100 (2006).\u003c/li\u003e\n \u003cli\u003eSchrag, A.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e Widening the Spectrum of Risk Factors, Comorbidities, and Prodromal Features of Parkinson Disease. \u003cem\u003eJAMA Neurol\u003c/em\u003e\u003cstrong\u003e80\u003c/strong\u003e, 161-171, doi:10.1001/jamaneurol.2022.3902 (2023).\u003c/li\u003e\n \u003cli\u003eSharma, S. \u0026amp; Pandey, S. Approach to a tremor patient. \u003cem\u003eAnn Indian Acad Neurol\u003c/em\u003e\u003cstrong\u003e19\u003c/strong\u003e, 433-443, doi:10.4103/0972-2327.194409 (2016).\u003c/li\u003e\n \u003cli\u003eTasks of the National Health Insurance Fund of Hungary (Hungarian acronym: NEAK) https://www.neak.gov.hu/oldalak/nyelvi-oldalak/english (accessed 02 May 2025).\u003c/li\u003e\n \u003cli\u003eSzigeti, S., Evetovits, T., Kutzin, J. \u0026amp; Ga\u0026aacute;l, P. Tax-funded social health insurance: an analysis of revenue sources, Hungary. \u003cem\u003eBull World Health Organ\u003c/em\u003e\u003cstrong\u003e97\u003c/strong\u003e, 335-348, doi:10.2471/blt.18.218982 (2019).\u003c/li\u003e\n \u003cli\u003eOECD/European Observatory on Health Systems and Policies (2024), Magyarorsz\u0026aacute;g: Eg\u0026eacute;szs\u0026eacute;g\u0026uuml;gyi orsz\u0026aacute;gprofil 2023, OECD Publishing, Paris, https://doi.org/10.1787/5adc0e05-hu.\u003c/li\u003e\n \u003cli\u003eV\u0026aacute;radi (2023). A mag\u0026aacute;nfinansz\u0026iacute;roz\u0026aacute;s m\u0026uacute;ltja, jelene \u0026eacute;s j\u0026ouml;vője Magyarorsz\u0026aacute;gon. IME Innov\u0026aacute;ci\u0026oacute; Menedzsment Eg\u0026eacute;szs\u0026eacute;g\u0026uuml;gy, 22(2), 6-15. https://doi.org/10.53020/IME-2023-201.\u003c/li\u003e\n \u003cli\u003eFolytat\u0026oacute;dik a mag\u0026aacute;neg\u0026eacute;szs\u0026eacute;g\u0026uuml;gy t\u0026eacute;rnyer\u0026eacute;se, Avaliable from: https://www.nn.hu/sajto/-/content/M5mewRibyh3R/2024-04-16-folytatodik-a-maganegeszsegugy-ternyerese (accessed 04 May 2025).\u003c/li\u003e\n \u003cli\u003eHayes, M. T. Parkinson\u0026apos;s Disease and Parkinsonism. \u003cem\u003eAm J Med\u003c/em\u003e\u003cstrong\u003e132\u003c/strong\u003e, 802-807, doi:10.1016/j.amjmed.2019.03.001 (2019).\u003c/li\u003e\n \u003cli\u003eLouis, E. D., Ottman, R. \u0026amp; Hauser, W. A. How common is the most common adult movement disorder? estimates of the prevalence of essential tremor throughout the world. \u003cem\u003eMov Disord\u003c/em\u003e\u003cstrong\u003e13\u003c/strong\u003e, 5-10, doi:10.1002/mds.870130105 (1998).\u003c/li\u003e\n \u003cli\u003eLouis, E. D. \u0026amp; Ferreira, J. J. How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. \u003cem\u003eMov Disord\u003c/em\u003e\u003cstrong\u003e25\u003c/strong\u003e, 534-541, doi:10.1002/mds.22838 (2010).\u003c/li\u003e\n \u003cli\u003eSong, P.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e The global prevalence of essential tremor, with emphasis on age and sex: A meta-analysis. \u003cem\u003eJ Glob Health\u003c/em\u003e\u003cstrong\u003e11\u003c/strong\u003e, 04028, doi:10.7189/jogh.11.04028 (2021).\u003c/li\u003e\n \u003cli\u003eLi, S. C.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e A prevalence survey of Parkinson\u0026apos;s disease and other movement disorders in the People\u0026apos;s Republic of China. \u003cem\u003eArch Neurol\u003c/em\u003e\u003cstrong\u003e42\u003c/strong\u003e, 655-657, doi:10.1001/archneur.1985.04060070045013 (1985).\u003c/li\u003e\n \u003cli\u003eGerbasi, M. E., Eldar-Lissai, A. \u0026amp; Lyons, K. E. Epidemiology of Pediatric Essential Tremor in the United States: A Systematic Literature Review from 2010 to 2020. \u003cem\u003eTremor Other Hyperkinet Mov (N Y)\u003c/em\u003e\u003cstrong\u003e12\u003c/strong\u003e, 11, doi:10.5334/tohm.681 (2022).\u003c/li\u003e\n \u003cli\u003eErro, R.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e Clinical correlates of \u0026quot;pure\u0026quot; essential tremor: the TITAN study. \u003cem\u003eFront Neurol\u003c/em\u003e\u003cstrong\u003e14\u003c/strong\u003e, 1233524, doi:10.3389/fneur.2023.1233524 (2023).\u003c/li\u003e\n \u003cli\u003eInzelberg, R.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e Essential tremor prevalence is low in Arabic villages in Israel: door-to-door neurological examinations. \u003cem\u003eJ Neurol\u003c/em\u003e\u003cstrong\u003e253\u003c/strong\u003e, 1557-1560, doi:10.1007/s00415-006-0253-5 (2006).\u003c/li\u003e\n \u003cli\u003eOkubadejo, N. U., Bankole, I. A., Ojo, O. O., Ojini, F. I. \u0026amp; Danesi, M. A. Prevalence of essential tremor in urban Lagos, Nigeria: a door-to-door community-based study. \u003cem\u003eBMC Neurol\u003c/em\u003e\u003cstrong\u003e12\u003c/strong\u003e, 110, doi:10.1186/1471-2377-12-110 (2012).\u003c/li\u003e\n \u003cli\u003eDotchin, C. L. \u0026amp; Walker, R. W. The prevalence of essential tremor in rural northern Tanzania. \u003cem\u003eJ Neurol Neurosurg Psychiatry\u003c/em\u003e\u003cstrong\u003e79\u003c/strong\u003e, 1107-1109, doi:10.1136/jnnp.2007.134304 (2008).\u003c/li\u003e\n \u003cli\u003eHornabrook, R. W. \u0026amp; Nagurney, J. T. Essential tremor in Papua, New Guinea. \u003cem\u003eBrain\u003c/em\u003e\u003cstrong\u003e99\u003c/strong\u003e, 659-672, doi:10.1093/brain/99.4.659 (1976).\u003c/li\u003e\n \u003cli\u003eVetterick, C., Lyons, K. E., Matthews, L. G., Pendal, R. \u0026amp; Ravina, B. The Hidden Burden of Disease and Treatment Experiences of Patients with Essential Tremor: A Retrospective Claims Data Analysis. \u003cem\u003eAdv Ther\u003c/em\u003e\u003cstrong\u003e39\u003c/strong\u003e, 5546-5567, doi:10.1007/s12325-022-02318-8 (2022).\u003c/li\u003e\n \u003cli\u003eLouis, E. D., Rohl, B. \u0026amp; Rice, C. Defining the Treatment Gap: What Essential Tremor Patients Want That They Are Not Getting. \u003cem\u003eTremor Other Hyperkinet Mov (N Y)\u003c/em\u003e\u003cstrong\u003e5\u003c/strong\u003e, 331, doi:10.7916/d87080m9 (2015).\u003c/li\u003e\n \u003cli\u003eLyons, K. E. \u0026amp; Pahwa, R. Pharmacotherapy of essential tremor : an overview of existing and upcoming agents. \u003cem\u003eCNS Drugs\u003c/em\u003e\u003cstrong\u003e22\u003c/strong\u003e, 1037-1045, doi:10.2165/0023210-200822120-00006 (2008).\u003c/li\u003e\n \u003cli\u003eLenka, A. \u0026amp; Louis, E. D. Primidone Intolerance in Essential tremor: Is it More than Just Age? \u003cem\u003eTremor Other Hyperkinet Mov (N Y)\u003c/em\u003e\u003cstrong\u003e11\u003c/strong\u003e, 57, doi:10.5334/tohm.672 (2021).\u003c/li\u003e\n \u003cli\u003eAit-Daoud, N., Hamby, A. S., Sharma, S. \u0026amp; Blevins, D. A Review of Alprazolam Use, Misuse, and Withdrawal. \u003cem\u003eJ Addict Med\u003c/em\u003e\u003cstrong\u003e12\u003c/strong\u003e, 4-10, doi:10.1097/adm.0000000000000350 (2018).\u003c/li\u003e\n \u003cli\u003eKapinos, K. A. \u0026amp; Louis, E. D. Prescription Drug Utilization among Patients with Essential Tremor: A Cross-Sectional Study of More Than 36,000 Patients. \u003cem\u003eMov Disord Clin Pract\u003c/em\u003e\u003cstrong\u003e11\u003c/strong\u003e, 1203-1211, doi:10.1002/mdc3.14155 (2024).\u003c/li\u003e\n \u003cli\u003eShah, C., Jackson, G. R., Sarwar, A. I., Mandava, P. \u0026amp; Jamal, F. Treatment Patterns in Essential Tremor: A Retrospective Analysis. \u003cem\u003eTremor Other Hyperkinet Mov (N Y)\u003c/em\u003e\u003cstrong\u003e12\u003c/strong\u003e, 10, doi:10.5334/tohm.682 (2022).\u003c/li\u003e\n \u003cli\u003eMa, T. T.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e Global trends in the consumption of benzodiazepines and Z-drugs in 67 countries and regions from 2008 to 2018: a sales data analysis. \u003cem\u003eSleep\u003c/em\u003e\u003cstrong\u003e46\u003c/strong\u003e, doi:10.1093/sleep/zsad124 (2023).\u003c/li\u003e\n \u003cli\u003eLukači\u0026scaron;inov\u0026aacute;, A.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e Prevalence, country-specific prescribing patterns and determinants of benzodiazepine use in community-residing older adults in 7 European countries. \u003cem\u003eBMC Geriatr\u003c/em\u003e\u003cstrong\u003e24\u003c/strong\u003e, 240, doi:10.1186/s12877-024-04742-7 (2024).\u003c/li\u003e\n \u003cli\u003eRosman, S., Le Vaillant, M. \u0026amp; Pelletier-Fleury, N. Gaining insight into benzodiazepine prescribing in General Practice in France: a data-based study. \u003cem\u003eBMC Fam Pract\u003c/em\u003e\u003cstrong\u003e12\u003c/strong\u003e, 28, doi:10.1186/1471-2296-12-28 (2011).\u003c/li\u003e\n \u003cli\u003eBarboza Zanetti, M. O.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e Consumption patterns and factors associated with inappropriate prescribing of benzodiazepines in Primary Health Care settings. \u003cem\u003ePLoS One\u003c/em\u003e\u003cstrong\u003e19\u003c/strong\u003e, e0309984, doi:10.1371/journal.pone.0309984 (2024).\u003c/li\u003e\n \u003cli\u003eGautam, D.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e Demographics of focused ultrasound thalamotomy for essential tremor and trends in deep brain stimulation surgery after its introduction in the USA. \u003cem\u003eBMJ Neurol Open\u003c/em\u003e\u003cstrong\u003e6\u003c/strong\u003e, e000582, doi:10.1136/bmjno-2023-000582 (2024).\u003c/li\u003e\n \u003cli\u003eSarica, C.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e Trends and disparities in deep brain stimulation utilization in the United States: a Nationwide Inpatient Sample analysis from 1993 to 2017. \u003cem\u003eLancet Reg Health Am\u003c/em\u003e\u003cstrong\u003e26\u003c/strong\u003e, 100599, doi:10.1016/j.lana.2023.100599 (2023).\u003c/li\u003e\n \u003cli\u003eBishay, A. E.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e Global Economic Evaluation of the Reported Costs of Deep Brain Stimulation. \u003cem\u003eStereotact Funct Neurosurg\u003c/em\u003e\u003cstrong\u003e102\u003c/strong\u003e, 257-274, doi:10.1159/000537865 (2024).\u003c/li\u003e\n \u003cli\u003eRavikumar, V. K.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e Cost-effectiveness of focused ultrasound, radiosurgery, and DBS for essential tremor. \u003cem\u003eMov Disord\u003c/em\u003e\u003cstrong\u003e32\u003c/strong\u003e, 1165-1173, doi:10.1002/mds.26997 (2017).\u003c/li\u003e\n \u003cli\u003eJameel, A.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e The cost-effectiveness of unilateral magnetic resonance-guided focused ultrasound in comparison with unilateral deep brain stimulation for the treatment of medically refractory essential tremor in England. \u003cem\u003eBr J Radiol\u003c/em\u003e\u003cstrong\u003e95\u003c/strong\u003e, 20220137, doi:10.1259/bjr.20220137 (2022).\u003c/li\u003e\n \u003cli\u003eLi, C.\u003cem\u003e\u0026nbsp;et al.\u003c/em\u003e Cost-Effectiveness of Magnetic Resonance-Guided Focused Ultrasound for Essential Tremor. \u003cem\u003eMov Disord\u003c/em\u003e\u003cstrong\u003e34\u003c/strong\u003e, 735-743, doi:10.1002/mds.27587 (2019).\u003c/li\u003e\n \u003cli\u003eDeuschl, G., Bain, P. \u0026amp; Brin, M. Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. \u003cem\u003eMov Disord\u003c/em\u003e\u003cstrong\u003e13 Suppl 3\u003c/strong\u003e, 2-23, doi:10.1002/mds.870131303 (1998).\u003c/li\u003e\n\u003c/ol\u003e"},{"header":"Tables","content":"\u003cp\u003e\u003cstrong\u003eTable 1.\u003c/strong\u003e \u003cstrong\u003eTremor-eliciting conditions and treatments in Group 6\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"330\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 41.6918%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTremor-eliciting conditions\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 58.3082%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNumber (percentage) of patients in Group 6\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 41.6918%;\"\u003e\n \u003cp\u003ealcohol abuse\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 58.3082%;\"\u003e\n \u003cp\u003e265 (0.65%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 41.6918%;\"\u003e\n \u003cp\u003ehyperthyroidism\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 58.3082%;\"\u003e\n \u003cp\u003e242 (0.59%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 41.6918%;\"\u003e\n \u003cp\u003edystonia\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 58.3082%;\"\u003e\n \u003cp\u003e164 (0.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 41.6918%;\"\u003e\n \u003cp\u003emultiple sclerosis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 58.3082%;\"\u003e\n \u003cp\u003e137 (0.34%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 41.6918%;\"\u003e\n \u003cp\u003eblepharospasm\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 58.3082%;\"\u003e\n \u003cp\u003e119 (0.29%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 41.6918%;\"\u003e\n \u003cp\u003etorticollis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 58.3082%;\"\u003e\n \u003cp\u003e30 (0.07%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 41.6918%;\"\u003e\n \u003cp\u003eWilson\u0026rsquo;s disease\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 58.3082%;\"\u003e\n \u003cp\u003e14 (0.03%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 41.6918%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTremor-eliciting treatments\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 58.3082%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNumber (percentage) of patients in Group 6\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 41.6918%;\"\u003e\n \u003cp\u003eamiodarone\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 58.3082%;\"\u003e\n \u003cp\u003e1,285 (3.15%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 41.6918%;\"\u003e\n \u003cp\u003evalproate\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 58.3082%;\"\u003e\n \u003cp\u003e849 (2.08%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 41.6918%;\"\u003e\n \u003cp\u003el-thyroxin\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 58.3082%;\"\u003e\n \u003cp\u003e403 (1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 41.6918%;\"\u003e\n \u003cp\u003elithium\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 58.3082%;\"\u003e\n \u003cp\u003e186 (0.45%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eWe found tremor-eliciting conditions in less than 3% of the patients; none had a frequency higher than 1%. Among the medications that might evoke enhanced physiological tremor, amiodarone was most frequently found, followed by valproate.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003cstrong\u003eTable 2.\u003c/strong\u003e \u003cstrong\u003ePharmaceutical and neurosurgical approaches in Group 6\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"368\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.8804%;\"\u003e\n \u003cp\u003e\u003cstrong\u003ePharmaceutical therapy\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 67.1196%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNumber (percentage) of patients in Group 6\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.8804%;\"\u003e\n \u003cp\u003ealprazolam\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 67.1196%;\"\u003e\n \u003cp\u003e17,911 (44%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.8804%;\"\u003e\n \u003cp\u003epropranolol\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 67.1196%;\"\u003e\n \u003cp\u003e10,410 (25.57%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.8804%;\"\u003e\n \u003cp\u003eclonazepam\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 67.1196%;\"\u003e\n \u003cp\u003e6,783 (16.66%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.8804%;\"\u003e\n \u003cp\u003eantiparkinsonian medication\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 67.1196%;\"\u003e\n \u003cp\u003e6,129 (15.05%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.8804%;\"\u003e\n \u003cp\u003eprimidone\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 67.1196%;\"\u003e\n \u003cp\u003e4,521 (11.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.8804%;\"\u003e\n \u003cp\u003etopiramate\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 67.1196%;\"\u003e\n \u003cp\u003e138 (0.33%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.8804%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNeurosurgical therapy\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 67.1196%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNumber (percentage) of patients in Group 6\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.8804%;\"\u003e\n \u003cp\u003edeep brain stimulation\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 67.1196%;\"\u003e\n \u003cp\u003e157 (0.39%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 32.8804%;\"\u003e\n \u003cp\u003eablative surgery\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 67.1196%;\"\u003e\n \u003cp\u003e33 (0.08%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eWe show the number and percentage of patients who picked up their prescription of the listed drugs from the pharmacy at least once during the study period. Most patients tried alprazolam, while propranolol was the second most preferred. Topiramate was dispensed to less than 0.5% of the patients. Less than 0.5% of the patients underwent neurosurgery, and the application of deep brain stimulation was almost 5 times as common as that of ablative surgery.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003cstrong\u003eTable 3.\u003c/strong\u003e \u003cstrong\u003eThe use of drug combinations in Group 6\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"654\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 27.9817%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eName of the\u0026nbsp;\u003cbr\u003e\u0026nbsp;medications\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNumber (%) of patients taking the combination in\u0026nbsp;\u003cbr\u003e\u0026nbsp;Group 6\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTime period of medication use (% of the total follow-up time (median and IQR)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eMedication use in months (median and IQR)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 27.9817%;\"\u003e\n \u003cp\u003epropranolol + alprazolam\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e2,749 (6.75%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e35.13 (13.35-68.12)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e30.00 (12.00-57.00)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 27.9817%;\"\u003e\n \u003cp\u003epropranolol + clonazepam\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e1,086 (2.67%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e30.11 (9.34-62.62)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e29.45 (9-64.09)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 27.9817%;\"\u003e\n \u003cp\u003eprimidone + alprazolam\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e962 (2.36%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e32.63 (11.38-60.26)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e30.95 (10.18-57.15)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 27.9817%;\"\u003e\n \u003cp\u003epropranolol + primidone\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e477 (1.17%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e25.78 (7.49-52.52)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e29.00 (7.67-58.00)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 27.9817%;\"\u003e\n \u003cp\u003eprimidone + clonazepam\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e443 (1.09%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e29.77 (8.99-61.99)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e29.00 (10-64.90)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 27.9817%;\"\u003e\n \u003cp\u003epropranolol + primidone + alprazolam\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e182 (0.45%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e16.54 (4.66-36.67)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e21.90 (5.62-48.42)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 27.9817%;\"\u003e\n \u003cp\u003epropranolol + primidone + clonazepam\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e138 (0.34%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e17.38 (5.42-41.69)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e22.62 (6.31-55.06)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 27.9817%;\"\u003e\n \u003cp\u003etopiramate + alprazolam\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e22 (0.05%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e26.67 (2.87-43.72)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e21.97 (3.78-53.32)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 27.9817%;\"\u003e\n \u003cp\u003etopiramate + clonazepam\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e20 (0.05%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e20.89 (5.94-62.00)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e26.65 (7.10-54.42)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 27.9817%;\"\u003e\n \u003cp\u003epropranolol + topiramate\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e19 (0.05%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e22.23 (5.96-48.71)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e21.23 (4.46-54.16)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 27.9817%;\"\u003e\n \u003cp\u003eprimidone + topiramate\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e13 (0.03%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e17.67 (4.48-51.99)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e17.90 (4.14-45.73)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 27.9817%;\"\u003e\n \u003cp\u003epropranolol + primidone + topiramate\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e4 (0.01%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e8.50 (1.01-20.30)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 24.0061%;\"\u003e\n \u003cp\u003e10.68 (1.33-31.95)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eThe table presents the number and percentage of patients using the certain drug combination and that how long these patients adhered to it. The most frequently used combination of two medications was propranolol + alprazolam, while propranolol + primidone + alprazolam was the most common triple choice.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003cstrong\u003eTable 4.\u003c/strong\u003e \u003cstrong\u003eTendencies for drug switch in Group 4\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cimg src=\"data:image/png;base64,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\" width=\"742\" height=\"451\"\u003e\u003c/p\u003e\n\u003cp\u003eWe looked for patients in the Not Parkinsonian Tremor Group (Group 6), who used antiparkinsonian medication before switching to one of the antitremor medications. Similarly, in case of the patients in the Parkinson\u0026rsquo;s disease/syndrome group (Group 7), we searched for those, who were first on an antitremor drug, which was later changed to antiparkinsonian medication. From the evaluation of the treatment switches, a small percentage of patients might be misdiagnosed with Parkinson\u0026apos;s disease/syndrome or essential tremor.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003cstrong\u003eTable 5.\u003c/strong\u003e \u003cstrong\u003eStratified age and gender analysis on the prevalence of essential tremor (Group 8) in Hungary\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 27.2727%;\"\u003e\n \u003cp\u003eAge of the patients (years)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.3636%;\"\u003e\n \u003cp\u003eEstimated prevalence of ET among men\u0026nbsp;\u003cbr\u003e\u0026nbsp;( /100.000 citizens)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.3636%;\"\u003e\n \u003cp\u003eEstimated prevalence of ET among women\u0026nbsp;\u003cbr\u003e\u0026nbsp;( /100.000 citizens)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 27.2727%;\"\u003e\n \u003cp\u003e\u0026lt;20\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.3636%;\"\u003e\n \u003cp\u003e263\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.3636%;\"\u003e\n \u003cp\u003e198\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 27.2727%;\"\u003e\n \u003cp\u003e20-29\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.3636%;\"\u003e\n \u003cp\u003e240\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.3636%;\"\u003e\n \u003cp\u003e182\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 27.2727%;\"\u003e\n \u003cp\u003e30-39\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.3636%;\"\u003e\n \u003cp\u003e123\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.3636%;\"\u003e\n \u003cp\u003e127\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 27.2727%;\"\u003e\n \u003cp\u003e40-49\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.3636%;\"\u003e\n \u003cp\u003e162\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.3636%;\"\u003e\n \u003cp\u003e197\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 27.2727%;\"\u003e\n \u003cp\u003e50-59\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.3636%;\"\u003e\n \u003cp\u003e281\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.3636%;\"\u003e\n \u003cp\u003e287\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 27.2727%;\"\u003e\n \u003cp\u003e60-69\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.3636%;\"\u003e\n \u003cp\u003e737\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.3636%;\"\u003e\n \u003cp\u003e739\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 27.2727%;\"\u003e\n \u003cp\u003e70-79\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.3636%;\"\u003e\n \u003cp\u003e1292\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.3636%;\"\u003e\n \u003cp\u003e1253\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 27.2727%;\"\u003e\n \u003cp\u003e\u0026gt;80\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.3636%;\"\u003e\n \u003cp\u003e823\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.3636%;\"\u003e\n \u003cp\u003e768\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 27.2727%;\"\u003e\n \u003cp\u003eAll\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.3636%;\"\u003e\n \u003cp\u003e351\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.3636%;\"\u003e\n \u003cp\u003e394\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eThe highest estimated prevalence was found in the elderly population between 70 and 79 years, followed by the prevalence in people over 80 years and those between 60 and 69 years of age. A slight female predominance exists.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003cstrong\u003eTable 6. \u0026nbsp; Prevalence of essential tremor in Europe\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 26.0188%;\"\u003e\n \u003cp\u003eCountry\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 24.4514%;\"\u003e\n \u003cp\u003eAge (years)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 26.489%;\"\u003e\n \u003cp\u003ePrevalence ( /100.000 citizens)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.0408%;\"\u003e\n \u003cp\u003eSample size (number of people)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 26.0188%;\"\u003e\n \u003cp\u003eFaroe Island\u003csup\u003e19\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 24.4514%;\"\u003e\n \u003cp\u003e\u0026ge;40\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 26.489%;\"\u003e\n \u003cp\u003e3100\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.0408%;\"\u003e\n \u003cp\u003e1,328\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 26.0188%;\"\u003e\n \u003cp\u003eFinland\u003csup\u003e15\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 24.4514%;\"\u003e\n \u003cp\u003e\u0026ge;40\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 26.489%;\"\u003e\n \u003cp\u003e550\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.0408%;\"\u003e\n \u003cp\u003e3,304\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 26.0188%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eHungary\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 24.4514%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAll ages\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 26.489%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e374\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.0408%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e59,676\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 26.0188%;\"\u003e\n \u003cp\u003eItaly\u003csup\u003e16\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 24.4514%;\"\u003e\n \u003cp\u003eAll ages\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 26.489%;\"\u003e\n \u003cp\u003e405\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.0408%;\"\u003e\n \u003cp\u003e7,653\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 26.0188%;\"\u003e\n \u003cp\u003eSpain\u003csup\u003e26\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 24.4514%;\"\u003e\n \u003cp\u003e\u0026ge;65\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 26.489%;\"\u003e\n \u003cp\u003e4800\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.0408%;\"\u003e\n \u003cp\u003e2000\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 26.0188%;\"\u003e\n \u003cp\u003eSpain\u003csup\u003e25\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 24.4514%;\"\u003e\n \u003cp\u003e\u0026ge;65\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 26.489%;\"\u003e\n \u003cp\u003e4800\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.0408%;\"\u003e\n \u003cp\u003e5,278\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 26.0188%;\"\u003e\n \u003cp\u003eSpain\u003csup\u003e18\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 24.4514%;\"\u003e\n \u003cp\u003e\u0026gt;65\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 26.489%;\"\u003e\n \u003cp\u003e8420\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 23.0408%;\"\u003e\n \u003cp\u003e753\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u0026nbsp;In the table, we present published data from other European countries. Our results are similar to the prevalence data from Italy (405/100,000), but the assessed prevalence in the other studies is substantially higher.\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"scientific-reports","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"scirep","sideBox":"Learn more about [Scientific Reports](http://www.nature.com/srep/)","snPcode":"","submissionUrl":"","title":"Scientific Reports","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Scientific Reports","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"epidemiology, essential tremor, Hungary, prevalence, therapy, tremor","lastPublishedDoi":"10.21203/rs.3.rs-6140908/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-6140908/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eThe published prevalence of essential tremor is variable worldwide and lacking in Central Europe. We aimed to estimate its prevalence in Hungary and to explore the locally applied therapeutic approaches. We collected data from the National Health Insurance Fund database and pharmacy database registered between 2010 and 2020. Matching the specified codes of the International Classification of Diseases and the individually tailored combination of interventions, we attempted to exclude Parkinson\u0026rsquo;s disease and other tremor evoking conditions.\u003c/p\u003e \u003cp\u003eWe estimated the period prevalence of essential tremor age standardized to the European Standard Population at 378\u0026ndash;388/100,000. After excluding patients with possible Parkinsonian syndromes, we found that 36.4% of patients with tremor did not take any medication during the study period. Most of the rest used alprazolam followed by propranolol for the longest period of time; the alprazolam and propranolol combination was the most preferred. Deep brain stimulation and ablative surgery were chosen for less than 0.5% of the patients.\u003c/p\u003e \u003cp\u003eOur strict methods probably underestimate the essential tremor prevalence in Hungary, which, however, does not differ considerably from international results. Given the limitations of medication therapy, expanding and improving neurosurgical interventions may help improve the quality of life of patients with essential tremor.\u003c/p\u003e","manuscriptTitle":"Prevalence estimation of essential tremor in Hungary between 2010 and 2020 based on the National Health Insurance Fund database","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-06-04 12:33:55","doi":"10.21203/rs.3.rs-6140908/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Accepted","date":"2025-07-22T06:52:22+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-07-20T19:56:49+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"191671891583431314322617164081590553989","date":"2025-06-27T15:57:52+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-06-25T18:47:53+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"121129186378095165935541598347712389918","date":"2025-06-25T18:17:00+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2025-06-25T15:24:56+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-05-27T09:56:01+00:00","index":"","fulltext":""},{"type":"submitted","content":"Scientific Reports","date":"2025-05-25T16:47:23+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"scientific-reports","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"scirep","sideBox":"Learn more about [Scientific Reports](http://www.nature.com/srep/)","snPcode":"","submissionUrl":"","title":"Scientific Reports","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Scientific Reports","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"ffc26357-0996-4f84-a1bc-4de30bc0f562","owner":[],"postedDate":"June 4th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[{"id":49099176,"name":"Health sciences/Diseases"},{"id":49099177,"name":"Health sciences/Health care"},{"id":49099178,"name":"Health sciences/Neurology"}],"tags":[],"updatedAt":"2025-08-11T16:08:49+00:00","versionOfRecord":{"articleIdentity":"rs-6140908","link":"https://doi.org/10.1038/s41598-025-13145-6","journal":{"identity":"scientific-reports","isVorOnly":false,"title":"Scientific Reports"},"publishedOn":"2025-08-05 15:57:01","publishedOnDateReadable":"August 5th, 2025"},"versionCreatedAt":"2025-06-04 12:33:55","video":"","vorDoi":"10.1038/s41598-025-13145-6","vorDoiUrl":"https://doi.org/10.1038/s41598-025-13145-6","workflowStages":[]},"version":"v1","identity":"rs-6140908","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-6140908","identity":"rs-6140908","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}